Dataset Viewer
Auto-converted to Parquet
id
stringlengths
11
17
article_id
stringlengths
8
11
path
stringlengths
11
60
text
stringlengths
1
118k
language
stringclasses
46 values
section_title
stringlengths
1
2.19k
domain
stringclasses
4 values
document_type
stringclasses
5 values
educational_score
float64
0
5.16
domain_scores
sequencelengths
0
3
document_type_scores
sequencelengths
0
4
language_score
float64
0
1
authors
sequencelengths
0
8.02k
article_url
stringlengths
3
63
license_url
stringclasses
16 values
PMC11276146_p0
PMC11276146
sec[0]/p[0]
Differentiated microbiotic habitats originate in the oral cavity at the level of the hard tissues of the teeth and in the soft tissues of the gingival sulcus, the back of the tongue, the lips, the cheeks and the palate . The microhabitats inside the pediatric oral cavity differ significantly in the absolute abundance of bacteria; furthermore, during night sleep, the oral microbiota are particularly dynamic, and this phenomenon makes the oral cavity a fertile ground for bacterial proliferation, which is also encouraged by poor oral hygiene (OH) and the reduction in saliva flow during a long night’s rest . The hard tissues represented by the teeth allow for the colonization of the aggregated bacterial biofilm, while the tongue and the soft tissues (mucous membranes) flake easily and constantly, allowing the bacterial biofilm to colonize other areas of the oral cavity more easily .
en
1. Introduction
biomedical
study
4.082031
[ 0.99951171875, 0.00023865699768066406, 0.00019180774688720703 ]
[ 0.9677734375, 0.00971221923828125, 0.02215576171875, 0.0002980232238769531 ]
0.999997
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p1
PMC11276146
sec[0]/sec[0]/p[0]
Dental caries is an infectious, degenerative and destructive disease affecting the hard substances of the tooth (the enamel and dentine); if not treated, they progress in depth up to the dental pulp. It has a multifactorial etiology: bacterial plaque plays a crucial role in its pathogenesis, as does a diet rich in sugars and reduced defense capacity of the host against pathogenic microorganisms . Other determining factors in the onset and progression of the carious process are the buffer capacity of saliva to neutralize the oral acid pH and the “time” factor, i.e., the synergistic action of food sugars and acidogenic bacteria—in particular, Streptococcus mutans , Streptococcus sobrinus and Lactobacillus . Socio-economic factors are also considered fundamental in the onset and progression of dental caries . Caries is a disease of various etiologies; during its different phases, pH, diet and acidogenic bacteria are decisive in the demineralization of the enamel, while other bacteria of proteolytic origin—in addition to acidogenic bacteria—are involved in progression in the dentin. Thus, carious disease has a polymicrobial etiology . The bacterial species associated with the onset and progression of caries include—in addition to S. mutans—Actinomyces and Bifidobacterium spp. . Groups of bacteria such as Streptococcus salivarius , S. sobrinus , Streptococcus parasanguinis , Scardovia wiggsiae , Slackia exigua , Lactobacillus salivarius , Parascardovia denticolens Porphyromonas , Actinomyces and Veillonella have been detected in the oral microbiota of children with deep caries . The bacterial species associated with the initiation and progression of caries (including Streptococcus , Actinomyces and Lactobacillus species) are microorganisms of saccharolytic origin, capable of metabolizing dietary carbohydrates to produce the lactic acid necessary to initiate the demineralization of the enamel . Through sugars, lactate dehydrogenase is activated, with predominant production of lactate. Pyruvate kinase increases glycolysis and lactate production . Veillonella species use lactate as the fundamental carbon and energy precursor molecule, switching it to pyruvate and succinate by means of enzymatic reactions. An overabundance of dietary carbohydrates increases the percentage of intracellular polysaccharides, which become reserves when the intake of extracellular sugars is reduced (e.g., between meals) . Early childhood caries (ECC) is a carious disease that begins before the age of six and sometimes even before the age of two. It is a multifactorial disease attributable, in most cases, to uncontrolled intake of dietary sugars, including honey and sweet drinks in general. ECC has prevalence rates ranging from 12 to 27% among children aged 2 to 3 years and from 27 to 48% among children aged 4 to 6 years. The impact of ECC in the United States is 3 to 28% . In the oral microbiota of affected children younger than 36 months, S. mutans was found to be largely implicated in the most important form of ECC. Other responsible pathogens in severe ECC include Scardovia wiggsiae and the Bifidobacteriaceae species of Porphyromonas and Actinomyces bacteria . Candida albicans plays a major role in ECC; in fact, it is frequently found in abundance in children with worrisome forms of ECC compared with children without caries .
en
1.1. Etiology of Caries
biomedical
review
4.964844
[ 0.99609375, 0.0022735595703125, 0.001781463623046875 ]
[ 0.35009765625, 0.00472259521484375, 0.64306640625, 0.0021038055419921875 ]
0.999995
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p2
PMC11276146
sec[0]/sec[1]/p[0]
Dental caries can have a negative impact on the health and quality of the young patient due to the pain, which causes a reduction in the appetite with consequent weight loss due to difficulties in chewing food and hypersensitivity to cold, heat and thermal and chemical stimuli, as well as acid in sugary foods and drinks. Furthermore, pain can compromise nighttime sleep, with negative consequences for academic performance . Untreated dental caries can be the consequence of pathologies even far from the oral cavity in children with special needs who suffer from chronic conditions such as seizure disorders. These children may be more susceptible to pneumonia, urinary tract infections, fever, generalized infections, and endocarditis in pediatric patients with congenital heart valve defects . Koerdt et al. found that S. mutans is the main pathogen present in the saliva of children with coronary heart disease . Pulpitis and recurrent dental abscesses can slow down a child’s body growth due to chronic systemic inflammation that affects metabolic pathways . The mechanism of action of this phenomenon could be attributed to proinflammatory cytokines such as interleukin-1 (IL-1), which can inhibit erythropoiesis by reducing the production of red blood cells in the bone marrow, resulting in anemia and chronic hematological disease .
en
1.2. Effects and Systemic Correlations of Dental Caries
biomedical
study
4.226563
[ 0.99951171875, 0.000377655029296875, 0.00028514862060546875 ]
[ 0.79248046875, 0.0033016204833984375, 0.2037353515625, 0.0005922317504882812 ]
0.999997
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p3
PMC11276146
sec[0]/sec[2]/p[0]
Microbial species, in particular bacteria, tend to organize themselves into biofilms to increase resistance to antibacterial agents, especially antibiotics, and ensure greater survival. Dental bacterial plaque is a biofilm formed by a polymicrobial aggregate that adheres to and colonizes the smooth surface of teeth, root surfaces and dental implants. It is incorporated into a polysaccharide matrix formed by mucins and antibodies, which contribute to forming the acquired film . The acquired film also acts as a protective matrix of the enamel against acid and mechanical insults and develops on the surface of the teeth immediately after thorough home OH or professional deplaquing. Planktonic cells adhere to the acquired pellicle through adhesins present in the peripheral cells, which intercept the matrix proteins through indeterminate physicochemical connections .
en
1.3. Dental Bacterial Plaque
biomedical
study
4.222656
[ 0.99951171875, 0.000400543212890625, 0.00017905235290527344 ]
[ 0.9404296875, 0.0303955078125, 0.0285491943359375, 0.0006971359252929688 ]
0.999996
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p4
PMC11276146
sec[0]/sec[3]/p[0]
The oral biofilm is able to alter the balance of the host microbiota, initiate oral dysbiosis and promote the onset of caries and periodontal diseases with reflections on systemic health .
en
1.4. Composition of Oral Bacterial Plaque
biomedical
other
2.945313
[ 0.998046875, 0.00113677978515625, 0.00098419189453125 ]
[ 0.027587890625, 0.95458984375, 0.01611328125, 0.0015916824340820312 ]
0.999998
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p5
PMC11276146
sec[0]/sec[3]/p[1]
Biofilm is considered a complex and effectively organized bacterial system responsible for the two most widespread oral diseases: tooth decay and gingival-periodontal diseases. The different oral environments presuppose a substantial difference in the bacterial species involved in biofilm formation; therefore, the supragingival bacterial population differs from the subgingival one . The primordial colonizing bacteria of the oral cavity area biofilm are streptococci (yellow complex), followed by Actinomyces species (green, blue and purple complexes) . Fusobacterium species (orange complex) play a central role that essentially allows for biofilm maturation by binding together the Gram-positive colonizing bacteria (cocci) and the Gram-negative bacteria of the red complex ( Porphyromonas ). Thus, a complex range of bacterial species that are related to each other are efficiently, stably and firmly aggregated . Actinomyces sp., Streptococcus sp., Lactobacillus sp., and Candida spp. constitute the most superficial substance of plaque. With plaque progression, through bacterial annexation, the transformation from a supragingival plaque of Gram-positive saccharolytic origin to a Gram-negative proteolytic plaque is determined by the accessibility of nutrients directly from saliva. Dissolved food nutrients in saliva represent the greater nourishment of supragingival plaque. In subgingival plaque, especially in deep pockets, the penetration of nutrients through saliva is limited; therefore, the major source of nourishment comes from tissues such as the periodontal and blood tissues. According to a study by Thurnheer et al., in subgingival plaque, Actinomyces sp. could survive and contribute to the formation of the dominant subgingival biofilm together with Fusobacteria and Tannerella sp. while P. gingivalis , P. intermedia , P. endodontalis and P. micra could form transient microcolonies of the biofilm .
en
1.4. Composition of Oral Bacterial Plaque
biomedical
study
4.644531
[ 0.9990234375, 0.0004875659942626953, 0.0005388259887695312 ]
[ 0.93505859375, 0.0012006759643554688, 0.06317138671875, 0.0003514289855957031 ]
0.999998
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p6
PMC11276146
sec[0]/sec[4]/p[0]
The oral district is populated by more than 700 species of microorganisms, including fungi, viruses and protozoa, where 58% have an official name, 16% are unnamed but have been cultivated and 26% are known only as uncultivated phylotypes . The tongue has the highest bacterial load of all oral tissues, hosting about two-thirds of the bacteria present in the oral cavity. These microorganisms are embedded in a thin mucus layer made up of complex extracellular polymeric substances . In numerical terms, over 100 bacteria can adhere to every unique coating cell on the surface of the tongue’s mantle, while at other sites of the mouth, only about 25 bacteria can colonize a single epithelial cell. The stable bacterial population of the tongue is mainly made up of aerobic and facultative anaerobic streptococci ( S. salivarius , S. mitis and S. sanguis ); furthermore, Veillonella (coconut) may reside in the crypts of the papillae . In the warm, humid environment of the tongue, there is a continuous migration of Gram-positive and Gram-negative bacteria, dead and disrupted cells and oral debris trapped between the folds and papillae, especially at the back. This physiological phenomenon is due to the dynamism of the biofilm present on the tongue, which is not organized and aggregated as on the tooth surfaces and the gingival edge, which develops a fairly independent microecosystem that pours easily into the saliva and which could contribute significantly and exponentially to increasing the accumulation of bacterial plaque on the teeth . In the microbiota of the dorsum of the tongue in children aged between 6 and 36 months, Tanner et al. detected, in the biofilm of the tongue coat of 171 children, S. mutans (the highest bacterial concentration of 70%), S. sobrinus (72%), Porphyromonas gingivalis (23%), Bacteroides forsythus (11%) and Aggregatibacter actinomycetemcomitans (30%). Bacterial species associated with caries included S. mutans in children aged between 18 and 36 months and Actinomyces israelii in children younger than 18 months; the latter species could be associated with an increase in bacterial plaque in children with caries. These bacterial colonies, found more frequently on the tongue than on the outside of the hard part of the tooth in children younger than 18 months, suggest that the tongue is a potential bacterial reservoir . As a result, lowering the bacterial load on the tongue coat can decrease plaque buildup on the teeth by reducing the colony-forming unit (CFU) value of carious bacteria in saliva, helping to more effectively prevent tooth decay, gum/periodontal disease and related systemic diseases . Proper oral hygiene, including tongue cleaning, is essential in the management and care of adult and pediatric patients in intensive care units (ICUs) to reduce the incidence of nosocomial infections that occur due to changes in oral microflora, typically within 48 h of presentation to the ICU .
en
1.5. Bacterial Biofilm on the Tongue
biomedical
study
4.679688
[ 0.9990234375, 0.0005736351013183594, 0.0003609657287597656 ]
[ 0.99267578125, 0.0006623268127441406, 0.0064697265625, 0.0002493858337402344 ]
0.999996
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p7
PMC11276146
sec[1]/p[0]
The aim of this review is to examine the scientific literature to clarify whether the mechanical removal of bacterial biofilm from the posterior tongue can have a positive effect on caries prevention and on the reduction in salivary streptococcal CFU and whole-mouth plaque index (FMPS), in order to identify a preventive protocol validated in the literature, allow for more effective prevention of caries and improve the oral and systemic health of pediatric patients.
en
2. Purpose of Work
biomedical
review
4.03125
[ 0.99072265625, 0.00643157958984375, 0.00279998779296875 ]
[ 0.005474090576171875, 0.0020465850830078125, 0.99169921875, 0.0006814002990722656 ]
0.999997
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p8
PMC11276146
sec[1]/sec[0]/p[0]
In order to provide a new guideline to healthcare professionals for the prevention of carious disease in pediatric patients, research was carried out on the inclusion of tongue cleaning in OH. We examined the English scientific literature, including literature reviews, case–control studies, cross-sectional studies and clinical studies, that investigated different tongue hygiene techniques in children.
en
2.1. Materials and Methods
biomedical
study
2.644531
[ 0.998046875, 0.0005931854248046875, 0.0013637542724609375 ]
[ 0.95068359375, 0.0247344970703125, 0.023712158203125, 0.0008821487426757812 ]
0.999997
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p9
PMC11276146
sec[1]/sec[0]/p[1]
The search for scientific articles was performed on 16 June 2024, in medical databases such as PubMed, Cochrane and Google Scholar. The data were extracted independently by two reviewers (C.M. and G.M.). A manual search was also performed to improve the pool of articles. The authors discussed the inclusion of each article, and the PRISMA flow diagram shows the flow of information through the different stages of the review process .
en
2.1. Materials and Methods
biomedical
review
2.679688
[ 0.99267578125, 0.0014410018920898438, 0.005901336669921875 ]
[ 0.37744140625, 0.03387451171875, 0.5869140625, 0.0015249252319335938 ]
0.999997
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p10
PMC11276146
sec[1]/sec[0]/p[2]
The keyword indicators used were “tongue cleaning in children” and “caries and systemic diseases and children”, for which inclusion and exclusion guidelines were drawn up. After preliminary screening and the removal of duplicates, the abstracts and titles of the articles were evaluated to include the articles and their citations that matched the keywords for full-text reading. A total of 154 articles were found to be suitable for full-text reading; of these, 60 focused on the OH protocol for the prevention and treatment of halitosis, 40 related to orthodontic situations, and 50 were not comprehensive about the technique of tongue cleaning used by the study participants. Finally, only four articles were eligible for qualitative analysis and were included in the present review.
en
2.1. Materials and Methods
biomedical
review
3.980469
[ 0.994140625, 0.0027332305908203125, 0.0031032562255859375 ]
[ 0.0125579833984375, 0.0014486312866210938, 0.98583984375, 0.00038886070251464844 ]
0.999998
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p11
PMC11276146
sec[2]/p[0]
The search revealed 28,580 total results. Initially, after removing duplicates, the titles and abstracts of the studies related to the keywords were considered to select the articles eligible for the reading of the full text. In total, 28,267 articles were excluded, and only 4 randomized studies, which met the search criteria, were included in the review ( Table 1 and Table 2 ).
en
3. Results
biomedical
review
3.828125
[ 0.98779296875, 0.004123687744140625, 0.0080718994140625 ]
[ 0.0092620849609375, 0.004108428955078125, 0.98583984375, 0.0005884170532226562 ]
0.999996
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p12
PMC11276146
sec[2]/p[1]
Overall, 183 children aged 9 to 12 years (mean age of 10.5 years) were involved in the included studies. The studies by Winnier et al. and Manju et al. , demonstrated that the total bacterial plaque index and CFU in S. mutans saliva were statistically significantly reduced in the OH groups with the brushing and scraping of the tongue at the first checkup after 7/10 days, maintaining or improving this result at the second checkup after 21 days. Winnier et al. divided 45 children into three single-blind experimental study groups; the first group (tongue brushing) and the second group (tongue scraping) had to combine tongue cleaning with OH (teeth and gum brushing) twice a day, while the third group had to brush their teeth without cleaning the tongue. The method of cleaning the tongue by using a scraper and a toothbrush has been shown to be equally effective in reducing the number of cariogenic bacteria; therefore, tooth brushing and tongue scraping were comparable in terms of efficacy in reducing the recorded bacterial plaque index (Silness and Loe) at baseline and after 10 and 21 days . Manju et al., in their single-blind randomized clinical study, divided 45 children into three distinct random groups: a tongue-scraping group, tongue-brushing group, and a group with mouth rinse with prepared saturated saline and nine small tablespoons of table salt in two-thirds of water. All the methods studied in the three groups proved to be effective in reducing the salivary CFU of S. mutans compared with the baseline at 7 and 21 days, with no differences among the groups . In the study by Chhaliyil et al., 2020 , in three experimental groups, a method for mechanically disintegrating bacterial plaque, easy and simple to employ anywhere, which involves rubbing the gums, teeth and tongue with the index finger and rinsing the oral cable with natural water (GIFTS method) after each meal, snack and intake of acidic or sugary drinks, was compared with conventional OH in the second study group, where the cleaning of the tongue with a toothbrush was always performed in combination with toothpaste (BT method), and with a toothbrush with nano-carbon toothpaste (CT method) in the third study group. The interruption of the organization of recent bacterial plaque, necessary for adhesion and a more complex microbial process, was evaluated as statistically significant. The mechanical action of the index finger, in the test group, at the 10-day checkup, showed that this simple mechanical maneuver was more effective than in the control groups in interfering with the early aggregation of bacterial plaque. In bacterial samples taken from the back of the tongue, the GIFTS and CT hygiene protocols made it possible to particularly lower the number of pioneers of Firmicutes. It was highlighted from the statistical results that the BT cleaning technique achieved the greatest decrease in the means of actinobacteria and phylum proteobacteria. An important abatement in Fusobacterium numbers in the crypts of the tongue microbiota was found, emphasizing that the tested hygiene practices interfere with the process of bacterial aggregation between the purple complex and the red complex. This result was demonstrated by the significant decrease in the phylum Bacteroidetes, especially Prevotella and Porphyromonas . On the basis of these findings, it could be suggested that OH, in synergy with tongue hygiene, promotes symbiosis in the oral environment . In the study by Sharma et al. , four study groups were compared to evaluate the effects on S. mutans salivary colonies of four different types of mouthwash, used after OH twice a day: group 1 performed rinses with 0.2% chlorhexdine gluconate; group 2 performed rinses with xylitol; group 3 performed rinses with antibacterial phytotherapeutic mouthwash (trade name of Himalaya-HiOra); group 4 performed rinses with distilled water. At the first checkup after seven days (without cleaning the tongue), the experimental groups obtained a reduction in S. mutans CFU with antibacterial mouthwashes; at the second checkup, at 14 days, with tongue cleaning being performed in all study groups, the introduction of tongue brushing significantly reduced the salivary CFU of S. mutans only in the control group (who rinsed the oral cavity with distilled water) . In a previous study, conducted by White et al., the greatest reduction in S. mutans CFU was recorded in the tongue-scraping group compared with the saturated saline rinse group, but the groups were adults with permanent dentition .
en
3. Results
biomedical
study
4.113281
[ 0.9990234375, 0.00051116943359375, 0.0004715919494628906 ]
[ 0.9375, 0.0006699562072753906, 0.061431884765625, 0.00021791458129882812 ]
0.999996
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p13
PMC11276146
sec[2]/sec[0]/p[0]
The included works have a low risk of bias; the contribution of new studies will be necessary to confirm the initial endpoint. Table 3 shows the risk of bias of the main articles examined. This review has a relatively low risk of bias.
en
Risk of Bias
biomedical
review
2.484375
[ 0.9609375, 0.0053253173828125, 0.03369140625 ]
[ 0.01329803466796875, 0.0163726806640625, 0.96923828125, 0.0009613037109375 ]
0.999999
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p14
PMC11276146
sec[3]/p[0]
Among the causes attributable to the onset of caries disease are poor OH, an unhealthy diet and microbiota dysbiosis .
en
4. Discussion
biomedical
other
2.324219
[ 0.99609375, 0.001117706298828125, 0.00275421142578125 ]
[ 0.058929443359375, 0.92333984375, 0.0159759521484375, 0.0018568038940429688 ]
0.999997
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p15
PMC11276146
sec[3]/p[1]
An analysis of the literature shows that the most frequent form of oral pathology in children is associated with bacterial plaque and manifests itself as gingivitis and caries . The results of this review underline that the greatest reduction in the plaque index and CFU in the saliva of S. mutans can be obtained with mechanical hygienic maneuvers, also avoiding or minimizing the use of antibacterial agents, which should be, inter alia, used only if necessary for a short time so as not to alter the balance of the host microbiota, interfere with oral symbiosis and cause drug resistance, especially in children with developing immune systems . Oral diseases and systemic correlations can, therefore, be prevented by combining OH of the tongue at both the domestic and professional levels. In this regard, the mechanical cleaning of the tongue is not always included in the protocols for the primary prevention of caries, while it is an integral part of the OH protocol for the prevention and treatment of bad breath, with conflicting results . S. mutans is released into the saliva from the back of the tongue and dental plaque, and the tongue, as already discussed, carries a higher level of bioburden than the other oral coatings . In the adult population, to remove more than 42% of oral biofilm (percentage ranging from 24% to 61% depending on the use of manual and electric toothbrushes and the individual’s manual and technical skills) , it is necessary to combine other OH strategies. The use of toothbrushes and interdental devices is suitable for limiting the FMPS and is becoming the gold standard for the instrumental containment of bacterial plaque, so much so that it is supported by the World Health Organization (WHO) . The inclusion of tongue cleaning, performed regularly during OH, allows for a significant reduction in medium-colonizing bacteria with a substantial reduction in Fusobacterium sp., compromising the maturation of bacterial plaque even in very young children and those without teeth . Furthermore, the frequent rinsing of the mouth with plain water after each snack further aids in the removal of food particles and debris from the tongue and teeth and in the destabilization of the oral bacterial biofilm . The frequent cleaning of the tongue and between the teeth is associated with better self-perceived oral health and a reduction in the FMBS. Data from the study by Rickenbacher et al., obtained from a population of 58 children, showed that the introduction of a professional tongue cleaner as an integral part of professional oral prophylaxis was well received by the young patients, and after a month during which they continued to clean their tongue at home, they stated that they wanted to continue in the future. Parents were also sensitized and involved in the project to allow for close collaboration aimed at strengthening preventive intervention . In this regard, involving parents or caregivers in oral screening and the instructions of the complete OH protocol can offer the unique opportunity to educate not only the pediatric population but also the adult one and forge a therapeutic–preventive alliance essential to achieving the goal of large-scale prevention .
en
4. Discussion
biomedical
review
4.296875
[ 0.98876953125, 0.006244659423828125, 0.005126953125 ]
[ 0.01111602783203125, 0.0010280609130859375, 0.9873046875, 0.0005249977111816406 ]
0.999998
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p16
PMC11276146
sec[3]/p[2]
In the Report on the Global State of Oral Health , the WHO requested urgent action to give people with health problems the opportunity to be treated, above all to guarantee prevention, with one ambitious goal of meeting oral health needs globally by 2030. Untreated carious disease of permanent teeth is the most widespread in the world with indecipherable prevalence (approximately 2 billion cases), followed by periodontitis, with about 1 billion people affected, and caries of milk teeth, with about 510 million cases. The prevention of tooth decay and its systemic correlates urgently reflects, therefore, the need in modern society for primary prevention which is easily available, immediate, effective, affordable for everyone and at the same time simple to implement from very early childhood, if not even before birth through oral hygiene and nutritional programs, intervening on modifiable risk factors for the unborn child from “zero” time, i.e., during pregnancy. There is a need for the strengthening of prevention and oral education programs in the first months of life and in pre-school age also through digital means to easily reach new mothers, especially during early childhood, to guarantee currently lacking oral educational projects throughout life .
en
4. Discussion
biomedical
review
3.890625
[ 0.99072265625, 0.003810882568359375, 0.005542755126953125 ]
[ 0.0092926025390625, 0.1737060546875, 0.81591796875, 0.0011930465698242188 ]
0.999998
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p17
PMC11276146
sec[4]/p[0]
Below, we propose OH protocols for the mucous membranes and tongue to be practiced with OH for a minimum of two times a day, not neglecting the time before bedtime.
en
5. Tongue-Cleaning Protocols
biomedical
other
2.011719
[ 0.9375, 0.050689697265625, 0.0117340087890625 ]
[ 0.003787994384765625, 0.9931640625, 0.0007777214050292969, 0.0024471282958984375 ]
0.999997
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p18
PMC11276146
sec[4]/sec[0]/p[0]
In the first months of the baby’s life, it is possible to use the appropriate wipes to clean the oral cavity after each feeding or, alternatively, to use sterile cotton gauze sufficiently soaked in physiological saline water.
en
5.1. Protocol for Hygiene of Tongue and Oral Cavity in Newborns
biomedical
other
1.993164
[ 0.90478515625, 0.0849609375, 0.01019287109375 ]
[ 0.00228118896484375, 0.9921875, 0.00047969818115234375, 0.004894256591796875 ]
0.999997
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p19
PMC11276146
sec[4]/sec[0]/p[1]
To clean a child’s oral cavity, the following steps are recommended: (1) Sit the child on your lap, facing one side. (2) Support their head with your arm and one hand. (3) Use the index finger and thumb of the hand supporting them to open their mouth. (4) Wrap the gauze around the index finger of the other hand. (5) Clean the palate, tongue and gums by gently rubbing them, with circular and posterior–anterior movements .
en
5.1. Protocol for Hygiene of Tongue and Oral Cavity in Newborns
biomedical
other
2.732422
[ 0.5947265625, 0.383056640625, 0.02203369140625 ]
[ 0.0014352798461914062, 0.98876953125, 0.0009069442749023438, 0.00890350341796875 ]
0.999998
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p20
PMC11276146
sec[4]/sec[1]/p[0]
After OH with an electric or manual toothbrush, place a tongue brush along the midline of the back of the tongue as far back as possible, avoiding reaching the point that could induce the gag reflex, then slide the toothbrush forward and backward with light pressure, in five sequences, from the back to the tip. Rinse the toothbrush under running water to remove residue, repeat the sequences on both sides of the tongue, and finally rinse the oral cavity vigorously with water to remove any debris and bacteria that have not completely detached .
en
5.2. Tongue-Cleaning Protocol with Toothbrush
biomedical
other
3.333984
[ 0.88623046875, 0.10430908203125, 0.00957489013671875 ]
[ 0.0027751922607421875, 0.99267578125, 0.0007944107055664062, 0.003719329833984375 ]
0.999997
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p21
PMC11276146
sec[4]/sec[2]/p[0]
After OH with an electric or manual toothbrush, place the tongue cleaner at the most proximal point to the root of the tongue mantle and perform posterior–anterior movements, gentle but decisive. Repeat the sequence five times, taking care to clean the instrument with water, and finish with a vigorous rinse .
en
5.3. Tongue-Cleaning Protocol with Tongue Scraper
biomedical
other
2.585938
[ 0.7578125, 0.206298828125, 0.035736083984375 ]
[ 0.001628875732421875, 0.994140625, 0.0007252693176269531, 0.0036182403564453125 ]
0.999996
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
PMC11276146_p22
PMC11276146
sec[5]/p[0]
Primary prevention is recommended to maintain health and reduce the possibility of disease onset. Daily tongue hygiene, two times a day, during OH, could be considered the gold standard for the prevention of carious disease. Furthermore, this simple mechanical maneuver is assimilated naturally if proposed from birth. The multidisciplinary preventive approach to oral health among professionals, healthcare workers (dental hygienists, pediatricians, nutritionists, etc.) and parents remains essential to protecting and promoting the overall health of the child. This review improves the understanding of the impact of tongue hygiene on controlling the bacteria responsible for the onset of carious disease and its systemic correlates; however, further research with more data is needed to further confirm the findings of this research.
en
6. Conclusions
biomedical
review
3.923828
[ 0.990234375, 0.005340576171875, 0.004306793212890625 ]
[ 0.0026454925537109375, 0.002925872802734375, 0.994140625, 0.00045943260192871094 ]
0.999997
[ "Giovanna Mosaico", "Mara Pinna", "Roberta Grassi", "Germano Orrù", "Andrea Scribante", "Carolina Maiorani", "Cinzia Casu", "Gianna Maria Nardi", "Andrea Butera" ]
https://doi.org/10.3390/children11070816
https://creativecommons.org/licenses/by/4.0/
39070602_p0
39070602
sec[0]/p[0]
Significant progress has been achieved over the last two decades in the development of tuberculosis treatment, with the discovery of new chemical entities and trials testing new combinations of drugs. This progress has resulted in substantial improvements in the treatment of tuberculosis, and the World Health Organization (WHO) has recommended shortened treatment regimens for drug-susceptible and drug-resistant tuberculosis. 1 – 3 With new chemical entities currently transitioning into clinical testing, the possibility of more efficacious, shorter and safer regimens for all forms of tuberculosis now appears to be achievable. 4
en
Introduction
biomedical
review
3.869141
[ 0.990234375, 0.006145477294921875, 0.0035648345947265625 ]
[ 0.003238677978515625, 0.0164642333984375, 0.9794921875, 0.0007653236389160156 ]
0.999997
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p1
39070602
sec[0]/p[1]
The early 2000s brought the discovery of new chemical entities with new modes of action on tuberculosis bacilli, 5 , 6 such as the development of diarylquinolines and nitroimidazoles, and the repurposing of active compounds traditionally used against Gram-positive infections (oxazolidinones); 7 all these developments played a major role in advancing new treatment options for drug-resistant tuberculosis. In parallel, WHO proposed new approaches to shorten the lengthy development pathway, breaking away from the classical approach of first testing single new compounds and then identifying the most suitable drug combination. 8 , 9
en
Introduction
biomedical
review
3.962891
[ 0.9970703125, 0.0015926361083984375, 0.0012216567993164062 ]
[ 0.0201873779296875, 0.0139007568359375, 0.96533203125, 0.0007266998291015625 ]
0.999997
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p2
39070602
sec[0]/p[2]
In 2017, WHO published Target regimen profiles for treatment of tuberculosis , promoting an end-to-end process integrating the development of new drugs within the development of new regimens, and defining specific requirements that new regimens should meet. 10 In view of the ground-breaking progress in tuberculosis treatment over recent years, and the subsequent transformations in the recommended standards of care by WHO, it is necessary to revise and update these target regimen profiles.
en
Introduction
biomedical
other
3.146484
[ 0.9873046875, 0.007656097412109375, 0.005168914794921875 ]
[ 0.006221771240234375, 0.86669921875, 0.1256103515625, 0.00141143798828125 ]
0.999993
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p3
39070602
sec[1]/p[0]
The revision of the target regimen profiles for tuberculosis treatment by WHO followed similar methods to those established for initial regimen development in 2016. The WHO Global Tuberculosis Programme established a Scientific Target Regimen Profile Development Group that included leading scientists and experts, public health officials, regulators, donors, programme managers and representatives of civil society organizations. Our group served to support the entire development process by reviewing drafts at several stages, contributing to discussions during meetings and assisting with the writing process.
en
Methods
biomedical
other
1.673828
[ 0.833984375, 0.010498046875, 0.155517578125 ]
[ 0.00440216064453125, 0.99267578125, 0.0027332305908203125, 0.0004191398620605469 ]
0.999994
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p4
39070602
sec[1]/p[1]
After a critical review of the 2016 document, our group retained the initial approach of classifying target regimen profiles for rifampicin-susceptible and rifampicin-resistant tuberculosis. Further, considering the possibility of developing a regimen composed of entirely new anti-tuberculosis drugs for which minimal or no resistance would exist, we maintained the pan-tuberculosis profile. We conducted a stakeholder survey during May–July 2022 to assess the use of the 2016 target regimen profiles, evaluate the relevance of the proposed regimen characteristics, prioritize these characteristics and evaluate potential trade-offs. The WHO Global Tuberculosis Programme commissioned two complementary modelling studies to inform our discussion. The first study estimated the potential health impact of novel treatments on the outcome of cure, considering various regimen characteristics such as treatment efficacy, duration, ease of adherence and forgiveness. The second study estimated the price thresholds below which novel rifampicin-susceptible tuberculosis and rifampicin-resistant tuberculosis regimens would be cost-neutral or cost-effective. 11
en
Methods
biomedical
study
4.097656
[ 0.9990234375, 0.00052642822265625, 0.000232696533203125 ]
[ 0.99560546875, 0.0005335807800292969, 0.003894805908203125, 0.00012624263763427734 ]
0.999996
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p5
39070602
sec[1]/p[2]
The target regimen profiles proposed here aim to guide the development of new tuberculosis treatment regimens, considering end-user needs and real-world conditions. We established a list of 13 characteristics – eight of which are common to all target regimen profiles (target population; populations of special interest; drug–drug interaction and metabolism; forgiveness of the regimen; number of component drugs; formulation or dosage form, dosing frequency and route of administration; propensity to develop resistance; and stability or shelf life); and five of which are regimen-specific (indication and need for drug susceptibility testing; efficacy; duration; safety, monitoring and tolerability; and pill burden) 11 – and identified minimal and optimal targets for each. The expectation is that any regimen that is developed will meet most of the minimal requirements and as many of the optimal requirements as possible.
en
Methods
biomedical
study
4.015625
[ 0.99853515625, 0.0010318756103515625, 0.00021505355834960938 ]
[ 0.98193359375, 0.00904083251953125, 0.00861358642578125, 0.00033593177795410156 ]
0.999996
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p6
39070602
sec[1]/p[3]
Based on this preliminary work, we developed an initial draft document that was shared with the group for revision and comments. We then divided into three subgroups who worked through virtual consultative meetings on each of the target regimen profiles, leading to a new version that was posted by WHO for public comment in February 2023. In March 2023, our group met to discuss the latest draft and reached full consensus on the contents of the document.
en
Methods
other
other
1.330078
[ 0.252685546875, 0.00965118408203125, 0.73779296875 ]
[ 0.006366729736328125, 0.99072265625, 0.00225830078125, 0.0006546974182128906 ]
0.999997
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p7
39070602
sec[2]/sec[0]/p[0]
Regimens should be intended for all population groups, irrespective of age, site of disease, clinical severity and co-morbidities. The regimens must have an acceptable safety profile, be well tolerated and efficacious in all these groups (including neonates, infants, children, women of reproductive age, and pregnant and lactating women), 12 as well as in those with comorbid conditions. Treatment developers should initiate paediatric studies as soon as a drug shows promising efficacy and safety in Phase 2 adult trials. 13
en
Target population
biomedical
other
3.855469
[ 0.93505859375, 0.0623779296875, 0.002471923828125 ]
[ 0.028717041015625, 0.94970703125, 0.01922607421875, 0.002140045166015625 ]
0.999996
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p8
39070602
sec[2]/sec[1]/p[0]
Human data indicate that the treatment does not cause any increased risk of structural abnormalities in the fetus, and the drugs are safe for women of childbearing potential, and pregnant and lactating women. The component drugs should be compatible with common forms of hormone-based birth control for women of reproductive age who do not wish to become pregnant.
en
Populations of special interest
biomedical
other
2.513672
[ 0.99462890625, 0.002513885498046875, 0.00272369384765625 ]
[ 0.018768310546875, 0.97021484375, 0.009674072265625, 0.0011816024780273438 ]
0.999995
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p9
39070602
sec[2]/sec[2]/p[0]
New chemical entities should have minimal or no drug–drug interaction with the other components of the regimen combination. For people living with human immunodeficiency virus undergoing antiretroviral therapy, drug–drug interaction studies should be initiated as soon as doses are known; ideally, no dose adjustments as a result of drug–drug interactions should be required. 14
en
Drug–drug interaction and metabolism
biomedical
other
3.507813
[ 0.9150390625, 0.08282470703125, 0.002277374267578125 ]
[ 0.007068634033203125, 0.9873046875, 0.002986907958984375, 0.002838134765625 ]
0.999997
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p10
39070602
sec[2]/sec[3]/p[0]
Imperfect adherence increases the risk of unfavourable treatment outcomes. 15 On this basis, forgiveness of a regimen, defined as “the degree to which regimen efficacy is unaffected by suboptimal adherence,” 11 was introduced as a new regimen characteristic. Because it can be challenging to ensure full daily drug administration under programmatic conditions, highly forgiving regimens are desirable.
en
Forgiveness of the regimen
biomedical
other
3.496094
[ 0.99560546875, 0.002391815185546875, 0.0021228790283203125 ]
[ 0.412109375, 0.52734375, 0.059539794921875, 0.0012273788452148438 ]
0.999998
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p11
39070602
sec[2]/sec[4]/p[0]
Regimens containing three to four drugs would provide the best balance to ensure high efficacy and minimize the risk of developing drug resistance. Further, limiting the number of component drugs in a regimen helps to minimize pill burden and safety risks, and facilitates drug coformulation.
en
Number of component drugs
biomedical
other
3.265625
[ 0.99169921875, 0.0057830810546875, 0.00254058837890625 ]
[ 0.00858306884765625, 0.984375, 0.006572723388671875, 0.0006337165832519531 ]
0.999998
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p12
39070602
sec[2]/sec[5]/p[0]
Formulation should be all-oral, with simple, age- or weight-based dose adjustment. Fixed-dose combination formulations as well as child-friendly formulations are strongly encouraged.
en
Formulation
biomedical
other
2.371094
[ 0.94677734375, 0.038482666015625, 0.01454925537109375 ]
[ 0.0012807846069335938, 0.99462890625, 0.0028133392333984375, 0.0011396408081054688 ]
0.999997
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p13
39070602
sec[2]/sec[6]/p[0]
Drugs included in the treatment regimen should protect each other against emergence of resistance; they should therefore have different targets, 16 have different pharmacokinetic–pharmacodynamic properties, be active and synergistic at the lesion site level, 17 and have half-lives that are well matched to reduce the risk of functional monotherapy.
en
Propensity to develop resistance
biomedical
other
3.849609
[ 0.99658203125, 0.00262451171875, 0.0006966590881347656 ]
[ 0.09393310546875, 0.88623046875, 0.018646240234375, 0.0010280609130859375 ]
0.999997
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p14
39070602
sec[2]/sec[7]/p[0]
Ideally, all component drugs should be stable for at least 5 years in climate zones III and IV (i.e. 30 °C and 75% relative humidity).
en
Stability and shelf life
biomedical
other
2.398438
[ 0.98681640625, 0.003376007080078125, 0.00988006591796875 ]
[ 0.01439666748046875, 0.984375, 0.0005764961242675781, 0.0004291534423828125 ]
0.999996
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p15
39070602
sec[3]/sec[0]/p[0]
Despite its wide availability, low cost and high efficacy, the current 6-month treatment of rifampicin-susceptible tuberculosis has several limitations, including adverse events, drug–drug interactions and adherence requirements. A 4-month regimen was recommended by WHO as non-inferior to the 6-month regimen in 2020, but its uptake remains limited because of its high cost, lack of a fixed-dose combination and concerns about the use of a fluoroquinolone. 11
en
Rifampicin-susceptible tuberculosis
biomedical
review
3.847656
[ 0.99560546875, 0.0031566619873046875, 0.0010471343994140625 ]
[ 0.0211639404296875, 0.028717041015625, 0.94921875, 0.0008826255798339844 ]
0.999996
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p16
39070602
sec[3]/sec[0]/sec[0]/p[0]
The rifampicin-susceptible tuberculosis regimen is indicated for patients with active tuberculosis disease caused by rifampicin-susceptible Mycobacterium tuberculosis strains, including forms with monoresistance to isoniazid, pyrazinamide and ethambutol (the other drugs included in the current 6-month treatment regimen).
en
Indication and drug susceptibility testing
biomedical
other
3.548828
[ 0.97900390625, 0.0196685791015625, 0.0013532638549804688 ]
[ 0.006999969482421875, 0.986328125, 0.0037689208984375, 0.0027599334716796875 ]
0.999996
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p17
39070602
sec[3]/sec[0]/sec[1]/p[0]
The current 6-month regimen of isoniazid, rifampicin, pyrazinamide and ethambutol has 90–95% efficacy under trial conditions. 18 The efficacy and duration targets aim to improve on the current 4-month WHO-recommended treatment (comprising the drugs isoniazid, rifapentine and moxifloxacin, with the addition of pyrazinamide in the first 2 months). However, the optimal target is based on the possible development of a 2-month regimen, as recently shown within the context of a sustained treatment monitoring strategy trial. 19
en
Efficacy and duration
biomedical
study
3.958984
[ 0.99853515625, 0.001171112060546875, 0.0002944469451904297 ]
[ 0.8408203125, 0.032867431640625, 0.1253662109375, 0.0008211135864257812 ]
0.999995
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p18
39070602
sec[3]/sec[0]/sec[2]/p[0]
Although serious adverse events with the current standards of care are uncommon, important tolerability issues affect adherence and, as a result, effectiveness. The safety and tolerability of a new rifampicin-susceptible regimen should be at least equal to, and ideally better than, the current standards of care. Demands for active clinical and laboratory monitoring for drug toxicity should be minimized.
en
Safety and tolerability
biomedical
other
3.701172
[ 0.9765625, 0.021270751953125, 0.001979827880859375 ]
[ 0.009307861328125, 0.9482421875, 0.04071044921875, 0.00177764892578125 ]
0.999996
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p19
39070602
sec[3]/sec[0]/sec[3]/p[0]
A regimen would ideally comprise just one pill per day; minimally, the pill burden should not be greater than for the 6-month regimen of isoniazid, rifampicin, pyrazinamide and ethambutol.
en
Pill burden
biomedical
other
3.074219
[ 0.9765625, 0.0201568603515625, 0.003078460693359375 ]
[ 0.004627227783203125, 0.9921875, 0.001934051513671875, 0.0013608932495117188 ]
0.999996
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p20
39070602
sec[3]/sec[1]/p[0]
In 2020, the global success rate for treatment of multidrug-resistant (MDR) tuberculosis (i.e. tuberculosis that is resistant to both rifampicin and isoniazid) was 60%. 20 Treatment typically lasted 9–18 months and included a large number of drugs, resulting in high pill burden and frequent side-effects that often led to discontinuation of treatment. The recently recommended bedaquiline, pretomanid, linezolid and moxifloxacin regimen promises improvements; however, the safety profile is still suboptimal 21 and careful implementation will be important to prevent emergence of resistance to component drugs. 22
en
Rifampicin-resistant tuberculosis
biomedical
review
3.927734
[ 0.9970703125, 0.002094268798828125, 0.0007567405700683594 ]
[ 0.03802490234375, 0.020172119140625, 0.94091796875, 0.0008254051208496094 ]
0.999995
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p21
39070602
sec[3]/sec[1]/sec[0]/p[0]
Under the minimal requirement, a rifampicin-resistant tuberculosis regimen is indicated for patients with active tuberculosis disease caused by rifampicin-resistant strains, with or without isoniazid resistance. Under the optimal requirement, the regimen is indicated for patients with active tuberculosis caused by either MDR tuberculosis, pre-extensively drug-resistant tuberculosis (caused by strains that are both MDR- and fluoroquinolone-resistant) or extensively drug-resistant tuberculosis (caused by strains resistant to any fluoroquinolones and at least one other Group A drug). 23 Drug susceptibility testing is essential before initiation of treatment to establish the resistance pattern of the strains and guide the composition of the regimen. Under the optimal requirement, susceptibility to the drugs in the regimen should be established through appropriate phenotypic or genotypic testing. In all cases, usage should be consistent with principles of good antibiotic stewardship. 24
en
Indication and drug susceptibility testing
biomedical
other
4.070313
[ 0.92822265625, 0.06964111328125, 0.002170562744140625 ]
[ 0.0191650390625, 0.93212890625, 0.0400390625, 0.00864410400390625 ]
0.999995
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p22
39070602
sec[3]/sec[1]/sec[1]/p[0]
The 2022 WHO tuberculosis treatment guideline update recommends the 6-month bedaquiline, pretomanid, linezolid and moxifloxacin regimen for most adult patients with tuberculosis that is MDR or rifampicin resistant. This regimen is approximately 90% efficacious. 25 Consequently, a new rifampicin-resistant-tuberculosis regimen should, at a minimum, have an efficacy at least as good as this newly recommended regimen and a similar duration; optimally, it should have a better efficacy and shorter duration than the 2022 regimen.
en
Efficacy and duration
biomedical
other
3.908203
[ 0.9326171875, 0.06402587890625, 0.0034160614013671875 ]
[ 0.008941650390625, 0.77294921875, 0.2110595703125, 0.00728607177734375 ]
0.999997
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p23
39070602
sec[3]/sec[1]/sec[2]/p[0]
The minimum and optimum targets are identical: it is suggested that the incidence and severity of adverse events with any new MDR-tuberculosis regimen should be lower than for the current regimens to guarantee best tolerability, acceptability and effectiveness under programmatic conditions. In the pivotal trial of the bedaquiline, pretomanid, linezolid and moxifloxacin regimen, adverse events of at least grade 3 occurring during treatment or up to 30 days after treatment were observed in 18% of patients (mainly hepatic, pancreatic or haematological disorders). 3 The proportion of patients discontinuing this regimen because of non-tolerability was 5%. 3
en
Safety and tolerability
biomedical
study
4.070313
[ 0.98876953125, 0.0106048583984375, 0.0004725456237792969 ]
[ 0.95947265625, 0.036041259765625, 0.003574371337890625, 0.000995635986328125 ]
0.999997
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p24
39070602
sec[3]/sec[1]/sec[3]/p[0]
A regimen would ideally comprise not more than four to five pills per day; minimally, the pill burden should not be greater than five to seven pills per day.
en
Pill burden
biomedical
other
2.580078
[ 0.9208984375, 0.06280517578125, 0.0160980224609375 ]
[ 0.0036487579345703125, 0.994140625, 0.0013027191162109375, 0.000972747802734375 ]
0.999997
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p25
39070602
sec[3]/sec[2]/sec[0]/p[0]
A regimen containing fully novel compounds with no cross-resistance could be used as a first-line tuberculosis regimen in individuals with tuberculosis disease without prior knowledge of the patient’s drug resistance profile. This approach would allow treatment to begin without delay while drug susceptibility testing is sought. Such a pan-tuberculosis regimen would be particularly useful in areas with a high prevalence of drug resistance and low availability of, or low access to, rapid drug susceptibility testing; current practice in such areas means that patients may be treated with inappropriate regimens and may continue to transmit disease and generate additional drug resistance. Under these conditions, population-level drug resistance surveillance will be an important component of the pan-tuberculosis strategy.
en
Indication and drug susceptibility testing
biomedical
other
3.970703
[ 0.9912109375, 0.00829315185546875, 0.0007305145263671875 ]
[ 0.07611083984375, 0.85546875, 0.064453125, 0.0037364959716796875 ]
0.999997
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p26
39070602
sec[3]/sec[2]/sec[1]/p[0]
Considering that a pan-tuberculosis regimen would be used to treat both rifampicin-susceptible and rifampicin-resistant tuberculosis, efficacy should be at least as good as the current rifampicin-susceptible tuberculosis regimen, with a duration of no more than 3–4 months. Optimally, efficacy should be better than the current regimen and, based on recent results indicating that a carefully applied monitoring strategy can make it possible to provide a cure with a 2-month regimen, 19 duration should be equal to, or less than, 2 months.
en
Efficacy and duration
biomedical
other
3.976563
[ 0.99072265625, 0.00823211669921875, 0.0010356903076171875 ]
[ 0.060546875, 0.505859375, 0.429931640625, 0.0034236907958984375 ]
0.999997
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p27
39070602
sec[3]/sec[2]/sec[2]/p[0]
In line with the recommendations for the rifampicin-susceptible and rifampicin-resistant tuberculosis regimens, and considering that the pan-tuberculosis regimen will be provided to a larger proportion of patients with rifampicin-susceptible than rifampicin-resistant tuberculosis, it is expected that the incidence and severity of adverse events should be lower and tolerability better than for the rifampicin-susceptible tuberculosis regimen, as both a minimal and an optimal target.
en
Safety and tolerability
biomedical
other
3.855469
[ 0.9892578125, 0.0096435546875, 0.0011835098266601562 ]
[ 0.04595947265625, 0.7998046875, 0.1519775390625, 0.001972198486328125 ]
0.999997
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p28
39070602
sec[3]/sec[2]/sec[3]/p[0]
A regimen would ideally comprise just one pill per day; minimally, the pill burden should not be greater than for the 6-month regimen of isoniazid, rifampicin, pyrazinamide and ethambutol.
en
Pill burden
biomedical
other
3.074219
[ 0.9765625, 0.0201568603515625, 0.003078460693359375 ]
[ 0.004627227783203125, 0.9921875, 0.001934051513671875, 0.0013608932495117188 ]
0.999997
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p29
39070602
sec[4]/p[0]
We discuss several key aspects that are relevant across all three regimens: drug susceptibility testing; adherence and forgiveness; treatment strategies; post-tuberculosis lung disease; and cost and access considerations.
en
Cross-cutting aspects
biomedical
review
2.953125
[ 0.9892578125, 0.005504608154296875, 0.00504302978515625 ]
[ 0.025970458984375, 0.2254638671875, 0.7451171875, 0.0035953521728515625 ]
0.999997
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p30
39070602
sec[4]/sec[0]/p[0]
Phenotypic or genotypic tests should be available at time of regimen introduction for both individual patient care and population-level surveillance. Drug developers need to support this by establishing minimum inhibitory concentration distributions and drug susceptibility testing interpretative criteria. To allow an understanding of resistance mechanisms, the identification of target genes and the development of rapid drug susceptibility testing, drug developers must also provide access to resistant mutants and drug compounds with detailed accompanying information (including stability, storage and solubility).
en
Drug susceptibility testing
biomedical
other
3.984375
[ 0.99267578125, 0.006702423095703125, 0.0006871223449707031 ]
[ 0.06585693359375, 0.9052734375, 0.026092529296875, 0.0026092529296875 ]
0.999997
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p31
39070602
sec[4]/sec[1]/p[0]
Poor adherence affects treatment outcomes and increases the risk of developing resistance, although uncertainty remains with regards to the magnitude of this effect. 26 A meta-analysis of trial participants receiving isoniazid, rifampicin, pyrazinamide and ethambutol suggested that those who missed 10% or more of treatment doses had a 5.9-fold greater risk of unfavourable treatment outcome. 15 This outcome suggests that imperfect adherence has a major impact on treatment outcomes and that, with the current dosing, such a regimen is unforgiving. However, studies to date present conflicting findings, showing considerable uncertainty about the degree to which improving adherence may enhance treatment outcomes. 27 High levels of poor adherence have been observed outside of well-controlled clinical trials; 27 developing more forgiving regimens that retain high proportions of patients cured under such circumstances – and are therefore effective and not just efficacious – is an important priority.
en
Adherence and forgiveness
biomedical
study
4.015625
[ 0.99853515625, 0.0008587837219238281, 0.0006246566772460938 ]
[ 0.6328125, 0.0012235641479492188, 0.365478515625, 0.0004355907440185547 ]
0.999998
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p32
39070602
sec[4]/sec[2]/p[0]
Beyond the specific characteristics of treatment regimens, novel treatment strategies such as stratified medicine approaches may be implemented to maximize the benefits and minimize the harms of treatment. Re-analyses of clinical trial data suggest that a difficult-to-treat subset of patients with rifampicin-susceptible tuberculosis may require longer than 6 months of the regimen to reach target cure, while most patients could be successfully treated in 4 months or less. 15 , 28 Further research is needed to investigate the use and applicability of stratified approaches for tuberculosis treatment under programmatic conditions.
en
Treatment strategies
biomedical
study
3.931641
[ 0.9990234375, 0.0007929801940917969, 0.00034046173095703125 ]
[ 0.560546875, 0.0075531005859375, 0.431396484375, 0.00069427490234375 ]
0.999996
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p33
39070602
sec[4]/sec[3]/p[0]
There is increasing recognition that pulmonary tuberculosis (both rifampicin-susceptible and rifampicin-resistant) may result in clinically significant lung injury and functional impairment, termed post-tuberculosis lung disease, even in patients whose treatment is otherwise successful. Developers are encouraged to incorporate evaluation of lung injury and functional impairment into trial designs. As our understanding of post-tuberculosis lung disease grows, developers may anticipate the inclusion of a new characteristic in future target regimen profiles: the ability to limit lung injury and functional impairment, and therefore the emergence of post-tuberculosis lung disease.
en
Post-tuberculosis lung disease
biomedical
review
3.941406
[ 0.99853515625, 0.001155853271484375, 0.000423431396484375 ]
[ 0.2249755859375, 0.207763671875, 0.56591796875, 0.001567840576171875 ]
0.999996
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p34
39070602
sec[4]/sec[4]/p[0]
Given the significant role of public financing for tuberculosis research and development, new products should be appropriately priced to reflect overall investments by global public and public–private actors, including governments, philanthropists, and other research and product sponsors. Any resulting product should deliver a public return on investment, and be linked to public health-driven priorities and application of the core principles of affordability, effectiveness, efficiency and equity. Developers should aim for new tuberculosis regimens that are cost-neutral, if not cost-saving, to health systems, considering both drug and non-drug costs. Our modelling analysis suggests that costlier regimens can still be cost-neutral if optimal regimen targets are met, as this would reduce non-drug costs (e.g. treatment monitoring visits or patient adherence support). 11 There should be collective efforts to ensure accelerated development, commercialization and scale-up of affordable regimens satisfying the criteria laid out in these target regimen profiles.
en
Cost and access considerations
biomedical
study
4.007813
[ 0.99609375, 0.0015096664428710938, 0.0021533966064453125 ]
[ 0.56787109375, 0.1026611328125, 0.32861328125, 0.0008740425109863281 ]
0.999998
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p35
39070602
sec[5]/p[0]
The 2023 update of the WHO target regimen profiles for tuberculosis treatment highlights key priorities for the next generation of tuberculosis treatments. However, it might not be feasible to fully meet all requirements simultaneously; developers may have to prioritize one or several characteristics over others, taking into consideration the intrinsic properties of the drugs included in the regimen and the health needs being targeted. Several perspectives can guide developers handling these trade-offs, including the clinical perspective (where probability of cure is a priority); the economic perspective (relating to the costs to health systems and patients); the patients’ perspective (drawing on experiences of tuberculosis survivors); and the expected long-term impact at the population level.
en
Discussion
biomedical
review
3.769531
[ 0.99609375, 0.0019073486328125, 0.0021915435791015625 ]
[ 0.0740966796875, 0.4091796875, 0.51513671875, 0.0012464523315429688 ]
0.999996
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p36
39070602
sec[5]/p[1]
We undertook a modelling analysis to estimate the impact on health outcomes and costs of improving various regimen characteristics. 11 In this analysis, ease of adherence (defined as the proportion of prescribed doses that patients take effectively while still on treatment) had the greatest influence on proportion of patients cured. For regimens meeting all the minimal characteristics of their respective target regimen profiles, complete adherence (as might be achieved via a long-acting injectable) increased the percentage of patients cured from 83% to 93% for rifampicin-susceptible tuberculosis, and from 74% to 85% for rifampicin-resistant tuberculosis. 11 Improving the efficacy of the regimen was the next most influential characteristic, especially for rifampicin-resistant tuberculosis. Of note, shortening treatment duration had a smaller effect on cure than other modelled characteristics, but had the greatest influence on reducing costs. 11 This finding aligns with observations from the stakeholders’ survey, in which respondents expressed that regimens should primarily demonstrate strong efficacy (even at the expense of longer duration), followed by safety, treatment duration, frequency of intake and pill burden.
en
Discussion
biomedical
study
4.125
[ 0.9990234375, 0.0007066726684570312, 0.00023126602172851562 ]
[ 0.998046875, 0.0002791881561279297, 0.0015268325805664062, 0.00011479854583740234 ]
0.999995
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p37
39070602
sec[5]/p[2]
Drug developers should therefore consider the capacity of their proposed regimen under development to be best used in programmatic conditions. Indeed, beyond the intrinsic pharmacological and antibacterial characteristics of new regimens, their clinical and public health impact will also depend on operational and epidemiological factors that affect regimen use (e.g. the ability to access, afford and distribute new regimens; the availability of clear guidance for clinicians; the background prevalence of antimicrobial resistance; and the development of resistance to new drugs). 29 For these reasons, the respective characteristics to be considered at the developmental stage should not be dissociated from the factors to be considered at implementation stage; we need effective regimens that are accessible, affordable and work for people and programmes, not just efficacious regimens that work well in clinical trials. To simplify regimen development, and ensure that products are fit for purpose and can meet the needs of affected communities (particularly in low-resource areas), developers should therefore (i) work within open collaborative models for tuberculosis research and development to enable early sharing of research knowledge; and (ii) consult affected communities to ensure that needs and priorities of patients are driving the final product and use-case.
en
Discussion
biomedical
other
4.042969
[ 0.99609375, 0.0029430389404296875, 0.0009613037109375 ]
[ 0.2335205078125, 0.42822265625, 0.3359375, 0.0023040771484375 ]
0.999998
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p38
39070602
sec[5]/p[3]
This target regimen profile update also highlights the deleterious impact of drug resistance. Developers should work in partnership with reference laboratories and diagnostic manufacturers to identify protocols and standards for phenotypic and genotypic tests, providing the necessary tools (compounds, mutants if available, information on drug resistance mechanisms) in parallel with drug development. A pan-tuberculosis regimen could facilitate implementation of tuberculosis treatment, but should be considered as a better first-line regimen for all and not a drug-susceptibility-testing-free regimen. The 2016 target regimen profile encouraged a shift in focus from drug to regimen development; the 2023 profiles draw awareness to considering not just regimens but treatment strategies to optimize care of patients.
en
Discussion
biomedical
other
3.876953
[ 0.99365234375, 0.005084991455078125, 0.0010251998901367188 ]
[ 0.043365478515625, 0.81201171875, 0.14208984375, 0.0023670196533203125 ]
0.999995
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39070602_p39
39070602
sec[5]/p[4]
In conclusion, the revised target regimen profiles described here represent an important step towards the development of new regimens for the treatment of all forms of tuberculosis. These profiles are expected to serve as a reference for research consortia involving drug developers, academics, public health institutions, nongovernmental organizations and civil society organization representatives, so that better treatment of all forms of tuberculosis is available to achieve the targets of the WHO end tuberculosis strategy. 30
en
Discussion
biomedical
other
3.005859
[ 0.99462890625, 0.0017833709716796875, 0.003391265869140625 ]
[ 0.0151214599609375, 0.96826171875, 0.0163116455078125, 0.0005373954772949219 ]
0.999994
[ "Christian Lienhardt", "Kelly E Dooley", "Payam Nahid", "Charles Wells", "Theresa S Ryckman", "Emily A Kendall", "Gerry Davies", "Grania Brigden", "Gavin Churchyard", "Daniela Maria Cirillo", "Eugenia Di Meco", "Ramya Gopinath", "Carole Mitnick", "Cherise Scott", "Farhana Amanullah", "Cathy Bansbach", "Martin Boeree", "Michael Campbell", "Francesca Conradie", "Angela Crook", "Charles L Daley", "Keertan Dheda", "Andreas Diacon", "Agnes Gebhard", "Debra Hanna", "Norbert Heinrich", "Anneke Hesseling", "David Holtzman", "Mathilde Jachym", "Peter Kim", "Christoph Lange", "Lindsay McKenna", "Graeme Meintjes", "Norbert Ndjeka", "Nguyen Viet Nhung", "Bern-Thomas Nyang’wa", "Nicholas I Paton", "Raghuram Rao", "Michael Rich", "Rada Savic", "Ingrid Schoeman", "Boitumelo Semete Makokotlela", "Mel Spigelman", "Eugene Sun", "Elin Svensson", "Phumeza Tisile", "Francis Varaine", "Andrew Vernon", "Mukadi Ya Diul", "Tereza Kasaeva", "Matteo Zignol", "Medea Gegia", "Fuad Mirzayev", "Samuel G Schumacher" ]
https://doi.org/10.2471/BLT.24.291881
https://creativecommons.org/licenses/by/3.0/igo/
39057070_p0
39057070
sec[0]/p[0]
The type 2 coronavirus that causes severe acute respiratory syndrome (SARS-CoV-2) is an obligatory intracellular pathogen that kidnaps the cell machinery that it needs for its replicative cycle. Lipidic interactions are essential during the entrance of this virus to the host cell and afterward for the budding process of new virions . The first step of the viral infection is the union of the spike protein (S) of the virus with (subunit S1) the angiotensin-converting enzyme 2 (ACE2), which contributes to a conformational change in the S2 subunit of the S protein, resulting in the binding of the virus with the transmembrane protein serine protease 2 (TMPRSS2). Both the TMPRSS2 and ACE2 are present in the lipid rafts that are microdomains in the cell membrane of the host . SARS-CoV-2 may use two mechanisms for its internalization: (1) fusion and (2) endocytosis. When fusion occurs, the viral glycoprotein S interacts with surface cell receptors, ACE2, as already mentioned, and then there is fusion of the membranes of the virus and the host. Endocytosis happens after fusion, and it is accompanied by invagination and transport. In this step, a diminished pH is required, which favors the union between the endosomal membrane and the viral envelope and the subsequent liberation of the nucleocapsid to the cytoplasm . However, the degree of virulence also depends on the pH of the extracellular environment, the membrane rigidity, the density of the receptors, and the amount of the viral spike proteins .
en
1. Introduction
biomedical
study
4.765625
[ 0.9990234375, 0.0006432533264160156, 0.0003864765167236328 ]
[ 0.990234375, 0.0020961761474609375, 0.007160186767578125, 0.0003600120544433594 ]
0.999996
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p1
39057070
sec[0]/p[1]
Lipids including phospholipids (PLs), fatty acids (FA), and cholesterol (CT) are essential nutrients that play important roles in anatomical and physiological functions such as cell signaling, death, and survival pathways in all cells. Furthermore, they are components of the bilipid plasma membrane and the membranes of the organelles . Bilipid membranes are conformed by CT and PL molecules, which constitute 50% of the total mass of the membrane, and the rest are constituted by structural proteins . In turn, PLs are made up of two FAs and a phosphate molecule. SARS-CoV-2 can reprogram the metabolism of the FA in the host cell to obtain it for the synthesis of the PLs necessary for the formation of the viral membrane of new virions. In this sense, the isomers of the transcription factor sterol regulatory element-binding protein (SREBP) are involved . The viral infection also stimulates the production of the bioactive FA mediators that participate in the host immune response, such as prostaglandins (PGs), thromboxanes (TXs), and leukotrienes (LKs), which are metabolites of the arachidonic acid (AA) pathway and are formed by cyclooxygenases (COXs), thromboxane synthase, lipo-oxygenase (LOX), and cytochrome P450 (CYP). These mediators participate as pro- and anti-inflammatory molecules in the infection process . Other FAs that may also play a pivotal role in the replication of SARS-CoV-2 are palmitic (PA), oleic (OA), linoleic (LA), stearic, and dihomo-γ-linoleic (D-γ-LA) acids. These FAs are very important for the formation and function of the viral membrane . In this sense, SARS-CoV-2 may contribute to an increase in the activity of the FA synthase (FAS) in the host cell. This enzyme is key in the synthesis of PA and is then used as a raw material for the synthesis of other FAs and becomes part of the lipid bilayer of membranes of the virus and facilitates virus propagation .
en
1. Introduction
biomedical
study
4.886719
[ 0.9990234375, 0.0007066726684570312, 0.0005049705505371094 ]
[ 0.99169921875, 0.0027484893798828125, 0.00476837158203125, 0.0005693435668945312 ]
0.999998
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p2
39057070
sec[0]/p[2]
In addition to FAs, other lipids, such as CT, which are abundant in the lipid rafts of the membrane where the ACE2 receptor is anchored, are important in viral pathways, such as their biosynthesis and assembly . Therefore, an intricate disturbance in lipid metabolism might happen in the process of infection and replication of SARS-CoV-2 for the benefit of the virus. Nevertheless, this leads to a decompensation of the pathways for lipid synthesis in the host that contributes to the clinical picture present in the patient, with a probable fatal outcome. The breakage of this intricate balance during the infection process is essential to reduce the clinical–pathological picture present in the patient. In this context, the regulation of lipid metabolism can be used as an adjuvant therapeutic target in patients infected by SARS-CoV-2 and as an addition to other strategies, including the battery of vaccines against this virus. In this sense, it has been demonstrated that supplementation with omega-3 FA (eicosapentaenoic acid EPA and docosahexaenoic DHA acid) or PLs enriched with EPA and DHA could reduce viral entrance to the host cells, ameliorate immune function, and diminishe the severity of some COVID-19 complications .
en
1. Introduction
biomedical
study
4.382813
[ 0.9990234375, 0.0006213188171386719, 0.00023949146270751953 ]
[ 0.73046875, 0.00299072265625, 0.265625, 0.0010576248168945312 ]
0.999997
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p3
39057070
sec[0]/p[3]
On the other hand, tocopherol, also known as vitamin E (Vit E), is an essential micronutrient and fat-soluble antioxidant in mammals that prevents the oxidation of FAs of the cell membranes by radical oxygen species (ROS), thus contributing to an increased fluidity of membranes and a decrease in lipid peroxidation (LPO) associated with the Haber–Weiss reaction . The rate of tocopherol decay is α > β > γ > δ, in association with the biological potencies of these forms of Vit E . Even though deficiencies in Vit E are rare in humans, they may occur by intestinal malabsorptive disorders, However, when they occur, they may lead to spinocerebellar ataxia, a decrease in motor control, lesions in both muscle and peripheral nerves, retinitis pigmentosa, macular degeneration, anemia, and lipoprotein disorders . Vit E also compromises the deficiency of both cell-mediated and humoral immune functions in animal trials. Moreover, supplementation with Vit E strengthens immunity and increases resistance against several pathogens . Moreover, Vit E acts synergistically with Vit C through the reduction in tocopheroxyl radicals .
en
1. Introduction
biomedical
review
4.660156
[ 0.998046875, 0.001010894775390625, 0.0010433197021484375 ]
[ 0.2064208984375, 0.004192352294921875, 0.7880859375, 0.00102996826171875 ]
0.999996
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p4
39057070
sec[0]/p[4]
Vit E supplementation (60 mg/7 day) decreased the LPO index in blood plasma and in the lung and liver in male mice with influenza . However, only a limited number of human trials have shown the effects of Vit E on resistance against infectious diseases, such as sepsis, compared to those performed in animals . The focus of these human trials was aimed at the elderly, who frequently contract respiratory diseases. Treatment with Vit E as a monotherapy has been poorly studied in COVID-19 despite the proposed beneficial effect of this treatment in various review manuscripts in the literature . Moreover, adjuvant therapy with Vit E supplementation could decrease the production of ROS and restore the balance in the alteration of the metabolism of PLs in patients with COVID-19, thus contributing to a decrease in the clinical manifestation in the progression of the infection . Therefore, the aim of this study was to demonstrate if treatment with Vit E as monotherapy is capable of restoring the modification of the FA in the PL profile in serum in patients with COVID-19.
en
1. Introduction
biomedical
study
4.140625
[ 0.99951171875, 0.0003294944763183594, 0.0001252889633178711 ]
[ 0.9990234375, 0.0004203319549560547, 0.00064849853515625, 0.00010156631469726562 ]
0.999998
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p5
39057070
sec[1]/sec[0]/p[0]
Ethical approval was obtained on 19 August 2020 . The protocol was registered . The Research and Ethics Committee of our institution approved the research protocol . This study was carried out according to the international ethical standards and the General Health Law, as well as the Helsinki Declaration, modified at the Congress of Tokyo, Japan. An informed consent form written for recruitment and the use of patient data were obtained from each patient, control subject, or their legal representative
en
2.1. Ethical Considerations
biomedical
other
1.469727
[ 0.9794921875, 0.00667572021484375, 0.01398468017578125 ]
[ 0.18603515625, 0.80908203125, 0.0012722015380859375, 0.0036945343017578125 ]
0.999997
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p6
39057070
sec[1]/sec[1]/p[0]
This was a prospective, analytical, open, and longitudinal (before–after) study run on 22 patients with COVID-19 who received Vit E treatment. The group before treatment with Vit E was compared with 23 healthy subjects (HSs), who constitute the control group. Inclusion criteria were patients with SARS-CoV-2 infection, who were 18 years old or older, belonged to both sexes with or without comorbidities, admitted to the intensive care unit (ICU) of the CITIBANAMEX Center, developed or did not develop septic shock and secondary to moderate or severe pneumonia by SARS-CoV-2 infection, and able to grant informed consent. The COVID-19 patients were considered to have septic shock when there was an acute increase in at least 2 points in the Sequential Organ Failure Assessment (SOFA) score, which includes the stage of neurological, respiratory, hemodynamic, hepatic, and hematologic conditions; they had lactate levels ≥ 2 mmol/L, and according to the conditions, the patients were dependent on a vasopressor for at least 2 h before recruitment. The SOFA score was also evaluated at admission and during the days of the treatment to determine organ dysfunction. Exclusion criteria were patients that were under chronic use (last 6 months) or recent use of Vit E and antioxidants, such as Vit C, statins, and steroids, patients that were not able to grant informed consent or refused to be included, and pregnant women or women that were breastfeeding.
en
2.2. Population of this Study
biomedical
study
4.167969
[ 0.982421875, 0.01708984375, 0.00045490264892578125 ]
[ 0.9912109375, 0.006969451904296875, 0.0007390975952148438, 0.0012598037719726562 ]
0.999998
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p7
39057070
sec[1]/sec[1]/p[1]
Treatment with Vit E was applied during the 2020 pandemic between the months of August and September and consisted of Vit E (α-tocopheryl acetate) capsules of 400 IU equivalent to 800 mg that were administered every 12 h/5 days. The patients were not vaccinated against SARS-CoV-2 because a vaccine had not yet been approved at the time this study was carried out. Hospitalized patients with COVID-19 were classified as severe or moderate according to their ventilatory status. COVID-19 patients with the severe condition require invasive mechanical intubation according to the Berlin criteria for acute respiratory distress syndrome (ARDS) . Patients were given individualized management according to an algorithm suggested by Soto et al., and they were not given hydroxychloroquine or antivirals . Treatment began before the recognition of the presence or absence of septic shock and during the first hour after admission. Depending on the hemodynamic status, management with crystalloid solutions and/or albumin was taken into account by means of dynamic indicators. If necessary, vasopressors were given to keep a mean arterial pressure (MAP) ≥ 65 mmHg. Inotropic drugs (dobutamine) were administered when myocardial dysfunction was present. Norepinephrine (NE) was the first option and/or vasopressin was used when there was a need to increase the MAP or reduce the NE dose. When there was a decrease in hemoglobin (<7.0 g/dL) in the absence of severe hypoxemia, myocardial ischemia, or severe bleeding, transfusion of blood packs was used. Mechanical ventilation with initial volumes of 6 mL/kg was used in ARDS patients . Plateau pressure was maintained at ≤30 cm H 2 O, and alveolar conduction pressure was ≤13 cm H 2 O. Positive end expiration pressure titration was managed by the use of the fraction of the inspired oxygen/positive end expiration pressure (FiO 2 /PEEP). Treatment with anticoagulants was based on the Thatched guidelines . Management with the prone position was necessary in patients with PaO 2 /FiO 2 of ≤150 mmHg . Standard therapeutic management with dexamethasone 8 mg, i.v., every 24 h for 7 days in all patients was given between 1 and 21 days of the onset of symptoms when not counterindicated. Pentoxifylline tablets of 400 mg were applied every 12 h by an oral route or a nasal-enteral tube for 5 days . They were counterindicated when there was a requirement of O 2 > 3 L, a progressive requirement of =2, PaO 2 /FiO 2 ≤ 250 mmHg, O 2 use plus bilateral infiltrates in the radiography, O 2 use plus DHL ≤ 250 U/L or ferritin ≥ 300 or DD ≥ 1000 ng/mL, or CPK ≥ 2 times the upper normal value. The following conditions were not considered as counterindications or relative counterindications: glucose > 250 mg/dL with hypoglycemia, hypokalemia < 3.3 meq, blood pressure > 155/95 mmHg with antihypertensive treatment, glaucoma, triglycerides (TGs) > 500 mg/dL (start treatment), a history of known peptic ulcers or bleeding from recent gastrointestinal tracts, untreated or decompensated dementia or psychiatric illness, and the use of non-potassium sparing diuretics or the use of inhaled B 2 agonists. The next conditions were monitored at follow-up: pre-prandial capillary glucose (7–13–1 h) for 10 days, even in fasting patients, MAP per shift, and basal potassium every 72 h. Some of the results related to this study were previously reported by Chavarría et al. during the before and after treatment with Vit E treatment evaluation . Figure 1 shows a flowchart of the recruitment of the patients and treatment with Vit E in the patients with COVID-19.
en
2.2. Population of this Study
biomedical
study
4.148438
[ 0.75390625, 0.2449951171875, 0.0013141632080078125 ]
[ 0.8251953125, 0.134033203125, 0.01209259033203125, 0.0287017822265625 ]
0.999996
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p8
39057070
sec[1]/sec[2]/p[0]
A total of 15 men and 8 women matched by age and gender who were negative for SARS-CoV-2 infection were included in the group of healthy subjects (HSs) and served as the controls. Autoimmune diseases, thyroid disease, obesity, overweight, dyslipidemia, arterial hypertension, diabetes mellitus, and inflammatory and degenerative diseases were not present in the HSs. The intake of antioxidant and non-steroidal anti-inflammatory drugs in HSs that could interfere with the results of this study was suspended 48 h before the sample was obtained. Biochemical variables such as glucose, calcium (Ca 2+ ), creatinine, uric acid, CT, TGs, high-density lipoproteins (HDLs), low-density lipoproteins (LDLs), and C-reactive proteins (CRPs) were determined.
en
2.3. Healthy Subjects
biomedical
study
4.007813
[ 0.9990234375, 0.0006742477416992188, 0.0002340078353881836 ]
[ 0.99951171875, 0.00031304359436035156, 0.0002281665802001953, 0.00008594989776611328 ]
0.999997
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p9
39057070
sec[1]/sec[3]/p[0]
Swab samples were collected from COVID-19 patients to apply the Paired Technique (nasopharyngeal and saliva). Samples were considered positive for SARS-CoV-2 when both the N1 and N2 protein primer presets were detected. Specific probes to detect the virus and the real-time reverse transcriptase polymerase chain reaction technique (qRT-PCR) were employed to determine the presence of the SARS-CoV-2 virus.
en
2.4. Detection of SARS-CoV-2 by a Real-Time Reverse Transcriptase Polymerase Chain Reaction
biomedical
study
4.0625
[ 0.99951171875, 0.0003223419189453125, 0.00016438961029052734 ]
[ 0.9990234375, 0.0008282661437988281, 0.00028061866760253906, 0.00008535385131835938 ]
0.999995
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p10
39057070
sec[1]/sec[4]/p[0]
A total of 10 mL of peripheral blood per patient were collected by venopuncture. The blood was centrifuged for 20 min at 936 g and 4 °C. The red blood cell pellet was discarded; the serum was recovered and collected in polypropylene tubes of 400 μL and stored at −30 °C until use. Interleukin-6 (IL-6), CRPs, TGs, HDLs, LDLs, glucose, urea nitrogen, creatinine, CT, Ca 2+ , hemoglobin, leukocytes, lymphocytes, platelets, albumin, D-dimer, fibrinogen, and ferritin were determined in the serum from the COVID-19 patients. Data from the patient’s medical history, including demographic data, prior illnesses to SARS-CoV-2 infection, COVID-19 test results, whether mechanical ventilation was used, and the type of treatment given, were used for the analysis of the results.
en
2.5. Peripheral Blood Samples
biomedical
study
4.097656
[ 0.9990234375, 0.0006537437438964844, 0.00016629695892333984 ]
[ 0.9990234375, 0.00044846534729003906, 0.0002529621124267578, 0.00010859966278076172 ]
0.999997
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p11
39057070
sec[1]/sec[5]/p[0]
The LPO index was measured indirectly through malondialdehyde MDA, and it was measured with a UV-2100 spectrophotometer at 532 nm (United Products and Instruments, Inc., 182-E Ridge Road Dayton, NJ, USA). A total of 100 μL of serum were used for this determination. Methanol with BHT at 4% (100 μL) and a KH 2 PO 4 buffer pH 7.4 (1 mL) were added to the sample and incubated at 37 °C for 30 min. Then, 2-thiobarbituric acid at 0.8 M (1.5 mL) was added and incubated at 90 °C for 1 h. Afterward, KCl at 5% (1 mL) plus n-butanol (4 mL) were added, and the sample was shaken for 30 sec and centrifuged at 4000 rpm for 2 min. The organic phase was extracted, and the absorbance was measured.
en
2.6. Determination of Markers of Lipid Peroxidation
biomedical
study
4.109375
[ 0.99951171875, 0.00022912025451660156, 0.0002053976058959961 ]
[ 0.99853515625, 0.0009899139404296875, 0.00025725364685058594, 0.00008147954940795898 ]
0.999997
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p12
39057070
sec[1]/sec[6]/p[0]
A total of 50 μL of serum were used for these determinations. The quantification of 8-isoprostane , thromboxane B 2 (TXB 2 ) , PGE 2 , and 6-keto-PGF 1α were provided by Cayman chemical , and IL-6 was provided by R&D systems as a biotechne and was measured at a wavelength range of 450–492 nm using a visible light microplate reader , according at the manufacturer’s specifications.
en
2.7. 8-Isoprostane, TXB 2 , PGE 2 , 6-keto-PGF 1α , and IL-6 Determinations
biomedical
study
3.984375
[ 0.99951171875, 0.00015032291412353516, 0.00019180774688720703 ]
[ 0.998046875, 0.00165557861328125, 0.00031828880310058594, 0.00008630752563476562 ]
0.999996
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p13
39057070
sec[1]/sec[7]/p[0]
For the extraction and derivatization of Vit E, saline solution 0.09% (1 mL respectively) and hexane (3 mL) were added to 100 µL of serum diethyl ether, and the samples were shaken with a vortex for 30 s and centrifuged at 3000 rpm for 4 min. The organic phase was recovered and evaporated under a stream of nitrogen. The residue was suspended with pyridine (200 mL) and hexamethyldesilazane (100 mL) and shaken in a vortex for 30 s. Then, chlorotrimethylsilane (50 mL) was added and derivatized at 60 °C for 20 min, and then hexane (3 mL) was added. The organic phase was recovered, filtered, and evaporated with a gentle stream of nitrogen . The calibration curve was carried out with 400 U α- tocopherol as standard and 12.5, 25, 50, 100, and 200 μL corresponding to 0.04, 0.08, 0.16, and 0.32 activity units. Vit E was identified by gas chromatography FID in a Carlo Erba Fratovap 2300 chromatograph (Calle Filadors, Sabadell, España) equipped with a capillary column packed with the stationary phase HP-FFAP (description: 30 m length × 0.320 mm diameter × 0.25 µm film) and fitted with a flame ionization detector at 240 °C with helium as the carrier gas at a flow rate of 1.2 mL/min. The areas under the peak were calculated using Cromatograf software version 1.1 coupled to a gas chromatograph.
en
2.8. Vitamin E Quantification in Serum
biomedical
study
4.167969
[ 0.99951171875, 0.00030517578125, 0.00018477439880371094 ]
[ 0.99853515625, 0.0011157989501953125, 0.00038242340087890625, 0.0001081228256225586 ]
0.999998
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p14
39057070
sec[1]/sec[8]/p[0]
For the extraction and derivatization of the TFA, 100 µL of serum were used according to the method described by Folch et al. in the presence of 50 µg of margaric acid (C17:0) as an internal standard. Then, 1 mL of a saline solution (0.09%) was added and mixed for 15 s, and then 2 mL of a methanol chloroform mixture (2:1 vol/vol) plus 0.002% BHT were added and centrifuged at 3000 rpm by 5 min. This step was repeated twice, and the organic phase was recovered and evaporated under a gentle current of nitrogen (N 2 ). TFAs were transesterified to their FA methyl esters by heating them at 90 °C for 2 h with 2 mL of methanol plus 0.002% BHT, 40 µL of H 2 SO 4 , and 100 µL of toluene. Afterward, 1 mL of the saline solution and 4 mL the hexane were added, and the mixture was centrifuged at 3000 rpm for 5 min. The hexane phase was recovered and evaporated under a gentle current of N 2 . The evaporated residue containing the FA was suspended in 100 µL of hexane, and 4 µL was injected into the chromatograph. The TFA methyl esters were separated and identified by gas chromatography FID in a Carlo Erba Fratovap 2300 chromatograph equipped with a capillary column packed with the stationary phase HP-FFAP (description: 30 m length × 0.320 mm diameter × 0.25 µm film) and fitted with a flame ionization detector at 210 °C with helium as the carrier gas at a flow rate of 1.2 mL/min. The areas under the peaks were calculated using Cromatograf software version 1.1 coupled to the gas chromatograph. The identification of each FA methyl ester was made by comparing their retention time with their corresponding standard .
en
2.9. Total Fatty Acid (TFA) Determination
biomedical
study
4.269531
[ 0.99951171875, 0.0003612041473388672, 0.00018739700317382812 ]
[ 0.99853515625, 0.0008082389831542969, 0.0005807876586914062, 0.00012254714965820312 ]
0.999998
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p15
39057070
sec[1]/sec[9]/p[0]
For fatty acid analysis in an acetone insoluble phospholipid fraction (FAAIPF) extraction, 200 μL of serum were used in the presence of 50 μg of L-γ-phosphatidylcholine-di-heptadecanoyl acid as internal standard plus acetone (1 mL) and 1 mL of saline solution (0.09%). The mixture was shaken 30 s and centrifuged at 1145 g at room temperature for 4 min. The supernatant was removed, and the button was suspended with 1 mL of the saline solution (0.09%) and mixed for 15 s, Then, a mixture of the chloroform–methanol with BHT (0.002%) was added (2:1, vol/vol, 4 mL) according to the method described previously . FAAIPFs were transesterified to their FAPL methyl esters and separated as described above . The acetone-insoluble phospholipid fraction is phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, and phosphatidic acid .
en
2.10. Fatty Acid Analysis in an Acetone Insoluble Phospholipid Fraction (FAAIPF) Determination in Serum
biomedical
study
4.152344
[ 0.99951171875, 0.000232696533203125, 0.000202178955078125 ]
[ 0.998046875, 0.001491546630859375, 0.0003108978271484375, 0.00009876489639282227 ]
0.999997
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p16
39057070
sec[1]/sec[10]/p[0]
The TPL determination in the serum was made with 100 µL of serum by a colorimetric assay through an enzymatic method utilizing N-ethyl-N-(2,hydroxy-3-sulfopropyl)-3,5-domethoxyaniline, according to the manufacturer’s recommendations (Fujifilm . The absorbance was measured at 600 nm. This method is able to detect lecithin, lysolecithin, and the sphingomyelin of phospholipids, but phosphatidyl ethanolamine is not measured in the sample.
en
2.11. Total Phospholipids (TPLs)
biomedical
study
4.085938
[ 0.99951171875, 0.00019824504852294922, 0.0001766681671142578 ]
[ 0.99609375, 0.0035152435302734375, 0.00041985511779785156, 0.00012826919555664062 ]
0.999999
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p17
39057070
sec[1]/sec[11]/p[0]
TFAs and PLs are expressed as a percentage. Categorical variables were expressed as frequencies and percentages. Continuous variables were compared with the Mann–Whitney U rank-sum test followed by the normality test (Shapiro–Wilk) between HSs vs. before treatment with Vit E in the COVID-19 patients and by the Kruskall–Wallis test before vs. after treatment with Vit E in the COVID-19 patients. The sample size was calculated by a paired test of two correlated means, specifying the standard error of the differences. The calculation was taken according to the data found in our study and previously reported in the article by Chavarría et al. . The calculation was based on two forms. The first was the percentage of cases with elevated LPO pre-treatment and post-treatment, which ranged between 1.75 and 1.05 with an estimated delta of 0.80 and an α error of 0.05 and 0.01, as well as a power of 0.84 and 0.99, respectively. We decided to take the calculation with an alpha error of 0.05 and a power of 84, and we included 22 patients, even if only 13 were required. Sigma Plot ® version 15 was used to generate the analysis and graphs. Differences were considered statistically significant when p ≤ 0.05.
en
2.12. Statistical Analysis
biomedical
study
4.089844
[ 0.99951171875, 0.00046634674072265625, 0.0002052783966064453 ]
[ 0.9990234375, 0.0006303787231445312, 0.00020444393157958984, 0.00007331371307373047 ]
0.999998
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p18
39057070
sec[2]/sec[0]/p[0]
A total of nineteen men (86%) and three (14%) women were included in the group of patients, with a median age of 55 years and a body mass index of 28. The comorbidities they presented were diabetes mellitus (27%), hypertension (14%), dyslipidemia (46%), overweight (41%), and morbid obesity (36%). Furthermore, the gasometry, blood biochemistry, and organ failure sequential score, along with demographic characteristics, are shown in Table 1 . The values are expressed as medians with a minimum and maximum range, and some values are reported as percentages.
en
3.1. Demographic Characteristics of the Patients with COVID-19
biomedical
study
3.564453
[ 0.98779296875, 0.01158905029296875, 0.0004069805145263672 ]
[ 0.99609375, 0.0025043487548828125, 0.000392913818359375, 0.0011682510375976562 ]
0.999996
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p19
39057070
sec[2]/sec[1]/p[0]
A total of fifteen men (55%) and eight (35%) women were included in the HS group, with a median age of 60 years, adding to a total of 23 individuals. The values of the levels of glucose, Ca 2+ , uric acid, creatinine, CT, HDLs, LDLs, TGs, and CRPs in these subjects are shown in Table 2 . The same variables in the serum of the patients with COVID-19 were also analyzed and are also shown in Table 2 . The COVID-19 patients showed a decrease in glucose levels, creatinine, and CT LDL ( p ≤ 0.01) and an increase in CRP (0.01) in comparison with the HSs.
en
3.2. Blood Biochemical Characteristics of the Healthy Subjects and COVID-19 Patients
biomedical
study
4.03125
[ 0.9990234375, 0.0004878044128417969, 0.00031065940856933594 ]
[ 0.99951171875, 0.00022113323211669922, 0.00018548965454101562, 0.00005894899368286133 ]
0.999998
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p20
39057070
sec[2]/sec[1]/p[1]
Table 3 shows the values of IL-6 and CRP in the HS and COVID-19 patients before and after treatment with Vit E. COVID-19 patients before treatment with Vit E showed an increase in these pro-inflammatory markers in comparison with HSs ( p = 0.001), but a decrease in both variables ( p = 0.01) was observed after treatment with Vit E.
en
3.2. Blood Biochemical Characteristics of the Healthy Subjects and COVID-19 Patients
biomedical
study
4.082031
[ 0.9990234375, 0.0005826950073242188, 0.00022280216217041016 ]
[ 0.99951171875, 0.00031566619873046875, 0.00025463104248046875, 0.00008231401443481445 ]
0.999997
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p21
39057070
sec[2]/sec[2]/p[0]
Figure 2 A shows that the Vit E concentration in COVID-19 patients was decreased ( p = 0.005) in comparison to HSs. However, treatment with Vit E favored an increase in these patients ( p = 0.04). Figure 2 B shows that the TPLs determined by colorimetry, which are represented by lecithin, lysolecithin, and the sphingomyelin of phospholipids, were decreased in the COVID-19 patients ( p = 0.01) in comparison with HSs and that treatment with Vit E increase them ( p = 0.05). Figure 2 C shows the mass of the fraction of the PLs in the serum, where there was a significant decrease ( p = 0.01) in COVID-19 patients versus HSs, and that treatment with Vit E favored a significant increase ( p = 0.04).
en
3.3. Vit E and Total Phospholipids
biomedical
study
4.101563
[ 0.99951171875, 0.0003352165222167969, 0.0002263784408569336 ]
[ 0.99951171875, 0.00019669532775878906, 0.00030875205993652344, 0.000057816505432128906 ]
0.999998
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p22
39057070
sec[2]/sec[3]/p[0]
Table 4 shows the percentage of TFAs in the serum of the HSs and patients with COVID-19. The PA, palmitoleic, and stearic, ( p ≤ 0.04) acids were decreased, but OA was increased ( p = 0.001) in patients with COVID-19 in comparison to HSs. The AA and EPA showed a tendency to increase but did not reaching a significant difference. However, treatment with Vit E increased the stearic, γ-linoleic, α-linoleic, D-γ-LA, and DHA ( p ≤ 0.02). The EPA showed a tendency to increase but did not reaching a significant difference. The same table also shows the TFA expressed in mg per mL in the serum, where treatment with Vit E only presented a tendency to decrease ( p = 0.07) without there being significant changes between the HS and COVID-19 patients.
en
3.4. Total Fatty Acids and Fatty Acids in an Acetone Insoluble Phospholipid Fraction (FAAIPF) in Serum
biomedical
study
4.101563
[ 0.99951171875, 0.00035834312438964844, 0.00025200843811035156 ]
[ 0.99951171875, 0.00018262863159179688, 0.0002532005310058594, 0.00005358457565307617 ]
0.999998
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p23
39057070
sec[2]/sec[3]/p[1]
Table 5 shows the composition of the saturated (SFA), monounsaturated (MUFA), and polyunsaturated-3, -6 (PUFA) acids in the serum in the patients with COVID-19 before and after treatment with Vit E and in the serum in the HSs. The total SFA decreased ( p = 0.02) and the MUFA increased ( p = 0.02) in patients with COVID-19. However, treatment with Vit E favored an increase in the PUFA-6 ( p = 0.01).
en
3.4. Total Fatty Acids and Fatty Acids in an Acetone Insoluble Phospholipid Fraction (FAAIPF) in Serum
biomedical
study
4.09375
[ 0.99951171875, 0.0003821849822998047, 0.0002033710479736328 ]
[ 0.99951171875, 0.00026416778564453125, 0.00028777122497558594, 0.00006747245788574219 ]
0.999998
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p24
39057070
sec[2]/sec[3]/p[2]
Table 6 shows the desaturation indexes, including the palmitoleic/PA ratio, which was decreased ( p = 0.01), and the stearic/OA, ratio which was increased ( p = 0.001). These ratios are usually used as indexes of ∆ 9 —the activity of desaturation. The ratio of γ-linoleic/linoleic that is used as an index of the desaturation ∆ 6 increased ( p = 0.001) in COVID-19 patients in comparison to HSs. However, treatment with Vit E in COVID-19 patients decreased ( p = 0.01). The AA/D-γ-LA index was increased ( p = 0.001), and the DHA/EPA tended to increase but did not reaching a significant difference ( p = 0.07). These indexes are used as indexes of ∆ 5 —the desaturase activity.
en
3.4. Total Fatty Acids and Fatty Acids in an Acetone Insoluble Phospholipid Fraction (FAAIPF) in Serum
biomedical
study
4.125
[ 0.99951171875, 0.000278472900390625, 0.00022912025451660156 ]
[ 0.99951171875, 0.000186920166015625, 0.00028014183044433594, 0.00005942583084106445 ]
0.999998
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p25
39057070
sec[2]/sec[3]/p[3]
Table 7 shows the FAAIPF percentage in the serum from the HSs and patients with COVID-19. The PA and stearic ( p = 0.002 and p = 0.01, respectively) increased, but OA and D-γ-LA tended to increase ( p = 0.07), and LA acid decreased, ( p = 0.001) in patients with COVID-19 in comparison to HSs. But, treatment with Vit E decreased the PA and D-γ-LA ( p = 0.03 and p = 0.01), respectively. The EPA and DHA showed a significant increase ( p = 0.01).
en
3.4. Total Fatty Acids and Fatty Acids in an Acetone Insoluble Phospholipid Fraction (FAAIPF) in Serum
biomedical
study
4.089844
[ 0.99951171875, 0.0002505779266357422, 0.0002434253692626953 ]
[ 0.99951171875, 0.00020372867584228516, 0.00023448467254638672, 0.0000508427619934082 ]
0.999997
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p26
39057070
sec[2]/sec[3]/p[4]
Table 8 shows the composition of the SFA, MUFA, and PUFA-3 and -6 in the FAAIPF in serum in the patients with COVID-19 before and after treatment with Vit E and in the HSs. The total SFAs increased ( p = 0.002), but the PUFA-3 decreased ( p = 0.002). However, treatment with Vit E favored an increase in the PUFA-6 ( p = 0.03) and tended to decrease the SFA ( p = 0.07).
en
3.4. Total Fatty Acids and Fatty Acids in an Acetone Insoluble Phospholipid Fraction (FAAIPF) in Serum
biomedical
study
4.125
[ 0.99951171875, 0.0004239082336425781, 0.00021946430206298828 ]
[ 0.99951171875, 0.0002789497375488281, 0.0002658367156982422, 0.0000655055046081543 ]
0.999996
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p27
39057070
sec[2]/sec[3]/p[5]
Table 9 shows the desaturation index in the FAAIPF. The stearic/OA ratio decreased ( p = 0.03) in COVID-19 patients in comparison to HSs, but treatment with Vit E in the COVID-19 patients tended to increase the index of the ∆ 5 desaturase through the DHA/EPA ratio, but there was no significant difference ( p = 0.07).
en
3.4. Total Fatty Acids and Fatty Acids in an Acetone Insoluble Phospholipid Fraction (FAAIPF) in Serum
biomedical
study
4.105469
[ 0.99951171875, 0.0002918243408203125, 0.0002472400665283203 ]
[ 0.99951171875, 0.0002396106719970703, 0.00018703937530517578, 0.00005626678466796875 ]
0.999998
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p28
39057070
sec[2]/sec[4]/p[0]
Figure 3 A shows the concentration of PGE 2 in the serum of the experimental groups; there was a significant increase in patients with COVID-19 in comparison with HSs ( p = 0.03), and after treatment with Vit E ( p = 0.01), it decreased. The same tendency was observed with the TXB 2 concentration in the patients with COVID-19 in comparison to HSs ( p = 0.01) and after treatment with Vit E ( p = 0.03). However, 6-keto PGF 1α decreased in the patients with COVID-19 vs. the same patients after treatment with Vit E in HSs .
en
3.5. Prostaglandins and Interleukin Concentration
biomedical
study
4.09375
[ 0.99951171875, 0.00037097930908203125, 0.0002448558807373047 ]
[ 0.99951171875, 0.0002237558364868164, 0.00025010108947753906, 0.00005805492401123047 ]
0.999995
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p29
39057070
sec[2]/sec[5]/p[0]
Figure 4 A shows that the LPO index and 8-isoprostane were significantly increased in the serum of the COVID-19 patients in comparison with HSs ( p = 0.001) after treatment with Vit E ( p = 0.001).
en
3.6. Lipid Peroxidation and 8-Isoprostene
biomedical
study
4.03125
[ 0.99951171875, 0.0003352165222167969, 0.0002751350402832031 ]
[ 0.99951171875, 0.0003039836883544922, 0.00022423267364501953, 0.000060439109802246094 ]
0.999999
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p30
39057070
sec[3]/p[0]
The SARS-CoV-2 virus responsible for the COVID-19 pandemic that devastated the world between 2020 and 2021 continues to mutate and still claims the lives of millions of people around the world. Although there are already different vaccines provided by different pharmaceutical companies against this virus (13.590 million vaccine doses have been administered and complete vaccination charts have been given to around 37% of the population, and the total population vaccinated with at least one booster dose of a COVID-19 vaccine is 32%), recent data from the WHO Coronavirus (COVID-19) Dashboard show that 7,044,637 people have died worldwide. For this reason, it is of vital importance to continue understanding both the metabolic pathways compromised by this virus in the patients and the possible use of adjuvant therapeutic agents that may contribute to combatting it. Adjuvant agents lead to lesser manifestations of the clinical data in patients and help to reduce the number of deaths. In this sense, Vit E, at a dose of 400 IU/day, has been utilized as an important anti-inflammatory and anti-OS therapy in humans with immunodeficiency and has a positive influence on the presence of the virus with promising results. This treatment decreases the viral load . In addition, it has been demonstrated that a decrease in Vit E is present in the plasma of patients with COVID-19 . Another study showed that in 49 patients diagnosed with COVID-19, a Vit E deficiency of 7% was present . Moreover, Vit E levels were lower in pregnant women with COVID-19 . Patients with COVID-19 also show an alteration in lipid metabolism characterized in part by a decrease in plasma PLs , which has been associated with Vit E deficiency. In this sense, the aim of this study was to demonstrate if treatment with Vit E restores the modification of the profile of the FA in the PLs in serum in patients with COVID-19.
en
4. Discussion
biomedical
study
4.25
[ 0.99951171875, 0.0004239082336425781, 0.0001493692398071289 ]
[ 0.99853515625, 0.0004642009735107422, 0.00079345703125, 0.00014412403106689453 ]
0.999994
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p31
39057070
sec[3]/p[1]
Our results show a decrease in Vit E levels in the serum of patients with COVID-19, which confirms the previously mentioned reports and suggests that in the infectious process caused by SARS-CoV-2, there is a depletion of molecules with antioxidant capacity, such as Vit E, which contributes to the progression of the infection and is associated with the inflammatory degree . In this sense, IL-6 and CRP, which are pro-inflammatory molecules, were elevated in the serum of the COVID-19 patients in our study. The rising viral load in COVID-19 results in a fast increase in inflammatory monocytes and neutrophils in the lungs in an effort to try to counteract the infection. These molecules further activate ILs and PGs that continuously and irreversibly affect the lung tissue . However, treatment with Vit E decreased the IL-6, CRP, PGE 2 , and TXB 2 levels and increased 6-keto-PGF 1α , which is an anti-inflammatory molecule. These results suggest that it is necessary to maintain and restore the levels of Vit E in the serum during the infection to reduce or control the progression of inflammation. A previous study evaluated the association between Vit E and COVID-19 and hypothesized that Vit E could amplify the immune system due to its antioxidant properties and its roles in maintaining the integrity of the T-cell membranes, thus reducing the duration of the infection . Therefore, our results suggest that treatment with Vit E effectively regulates the immune activity that confers protection against SARS-CoV-2 by decreasing IL-6 and CRP . In this regard, it has been reported that the most important effects of Vit E supplementation on immune system activities include post-mitogenic stimulation, lymphocyte proliferation, and an increase in delayed-type hypersensitivity . Studies in vitro and in vivo have demonstrated that Vit E treatment improves naive T-lymphocytes, natural-killers, and dendritic cell activities to promote the initiation of T-cell activation. It also inhibits the production of pro-inflammatory cytokines, such as IL-1, -6, -8, and TNF-α, but stimulates the IFN system, which exerts antiviral activities .
en
4. Discussion
biomedical
study
4.375
[ 0.99951171875, 0.0004737377166748047, 0.00016176700592041016 ]
[ 0.99853515625, 0.0003342628479003906, 0.0010156631469726562, 0.00015425682067871094 ]
0.999998
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p32
39057070
sec[3]/p[2]
Moreover, high levels of LPO are present in the inflammatory process, and these are in part the result of ferroptosis present in these patients . Our results showed an increase in the LPO index in patients with COVID-19 in comparison to HSs. Moreover, treatment with Vit E favored a decrease. This suggests that Vit E supplementation is capable of decreasing the LPO index associated with the increase in ferroptosis . In this regard, Vit E reacts with peroxyl radicals to prevent the formation of lipid hydroperoxides associated with the FA oxidation of the cell membrane. Afterward, glutathione (GSH) and enzymes that employ GSH may detoxify oxidized lipids . Furthermore, Vit E deficiency is related to ferroptosis, and other studies suggest that Vit E supplementation at a high dose of 500 mg/kg may act as a treatment to inhibit ferroptosis in COVID-19 patients and decrease the damages caused by ferroptosis to multiple organs, such as the lung, kidney, liver, gut, heart, and nervous system . Our results show an increase in ferroptosis in COVID-19 before treatment with Vit E. However, we could not validate whether ferroptosis decreased in these patients after treatment with Vit E, and, therefore, more studies are required to confirm this. Nevertheless, there was a significant decrease in LPO.
en
4. Discussion
biomedical
study
4.132813
[ 0.99951171875, 0.00028514862060546875, 0.00016760826110839844 ]
[ 0.99951171875, 0.00019943714141845703, 0.00037407875061035156, 0.00007492303848266602 ]
0.999999
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p33
39057070
sec[3]/p[3]
The increase in LPO in COVID-19 suggests that an oxidizing background in the SARS-CoV-2 infection has already been documented . This situation favors the oxidation of the AA to 8-isoprostanes, which are molecules considered markers of LPO and oxidative injury. For this reason, this molecule has been considered an ideal marker in the broncho-alveolar lavage fluid of patients with interstitial lung disease . Our results revealed a statistically significant elevation of 8-isoprostane in COVID-19 patients, and there was a decrease in its level after of treatment Vit E. This suggests that 8-isoprostane may be a predictive marker against the OS present in these patients and reinforces that Vit E supplementation contributes to decreasing the oxidizing background. In patients co-infected with malaria and COVID-19, treatment with Vit E decreases 8-isoprostane levels .
en
4. Discussion
biomedical
study
4.105469
[ 0.99951171875, 0.00026726722717285156, 0.00014853477478027344 ]
[ 0.9990234375, 0.0002810955047607422, 0.00040602684020996094, 0.00007975101470947266 ]
0.999997
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p34
39057070
sec[3]/p[4]
Regarding the results of the TPL fractions obtained (lecithin, lysolecithin, and sphingomyelin), the patients with COVID-19 showed a significant decrease in serum. Different studies in COVID-19 have demonstrated an alteration in the profile of the lipid metabolism in this disease . Therefore, the rescheduling of the FA metabolism in the host seems to be essential . The decrease in the mass fraction in the TPLs of the lecithin, lysolecithin, and sphingomyelin quantified could be due in part to their use in the formation of new viral membranes and the reparation of the membrane of the host cell after the budding process; they can also restore the high oxidation by free radicals that result in oxidized PLs, which contribute to the LPO index. However, treatment with Vit E was capable of diminishing this , and as the results demonstrate, the administration of 500 mg/d of Vit E for 12 weeks in patients with hepatitis C virus showed an increase in total PUFAs in red blood cells of the PLs since it has been described that Vit E can exert its maximum protective effect in a concentration of 1 molecule for every 2000 PL molecules . In addition, the analysis of the FAAIPF showed an increase in the PA and stearic acid and a decrease in the LA in this study. However, in the TFA, the PA, palmitoleic, and stearic acids showed a decrease. These results might seem paradoxical; however, these alterations may be due in part to the need for host membranes to be repaired as the budding process of new virions occurs. In this sense, our results show that the TFA in the serum tends to increase in COVID-19 patients. At this stage, there is a greater demand for the synthesis of FAs. There is also a great need for these molecules for the formation of the viral membrane and because they are necessary for binding to the receptor-binding domain, such as the LA . However, treatment with Vit E may restore these requirements . In this sense, it has been demonstrated that the FA of the PLs in the serum reflects the FA from PLs in the membranes of erythrocytes .
en
4. Discussion
biomedical
study
4.332031
[ 0.99951171875, 0.00038814544677734375, 0.00020456314086914062 ]
[ 0.9990234375, 0.00026416778564453125, 0.0005059242248535156, 0.00010162591934204102 ]
0.999997
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
39057070_p35
39057070
sec[3]/p[5]
In addition, the desaturation process constitutes an important step in the metabolism of FAs, and desaturases are key enzymes in the biosynthesis of the MUFA from the SFA. These enzymes introduce a cis-double bond into the SFA, which is very important in the control of the structural, fluidity, and disorders of the membrane . Our results show significant changes in the activities of ∆ 9− , ∆ 6− , and ∆ 5− desaturases in the serum of the patients with COVID-19, but treatment with Vit E restored the activities of these enzymes, both in the FA and TPL. These results suggest that there is an alteration in the activity of desaturases in the SARS-CoV-2 infection, but supplementation with Vit E restores them. The disorders associated with an imbalance in the activity of desaturases include modifications in membrane ionic transport, receptor accessibility, and cellular enzymatic activities . Our results evidenced the modification in the proportions of the SFA, MUFA, TFA, SFA, and PUFA n-3 of the FAAIPF. However, treatment with Vit E restored them and even increased PUFA n-6 in both the TFA and FAAIPF. This result suggests that there exists an alteration in the proportion of the SFA and MUFA in the SARS-CoV-2 infection but that the supplementation with Vit E restores it. The increase in PUFA n-6 or the tendency in PUFA n-3 in both the TFA and FAAIPF is important because even though we did not provide a diet with -3 or -6, these molecules were increased. These FAs influence the immune response. They are essential elements since there is a need to consume them in the diet because they cannot be endogenously synthesized. The PUFA-3 fatty acids largely comprise α-linolenic acid, DHAs, and EPAs. These FAs may trigger anti-inflammatory reactions in the body. Also, both PUFA-3 and -6 can change the composition of the PL bilayer of the host cell membrane, thereby preventing viral entry. When incorporated into the plasma membrane, they can affect the clumping of toll-like receptors associated with the prevention of signals that activate NF-κB, the production of other pro-inflammatory mediators, and the reduction in clinical complications in COVID-19 patients . Furthermore, DHAs and EPAs also serve as precursors of resolvins, which reduce the production of pro-inflammatory mediators, eventually resulting in a decrease in systemic inflammation . In this sense, there exists an interrelation between Vit E and PUFA n-3 and -6. For example, the supplementation with Vit E increased the levels of PUFA n-3 and decreased the levels of SFAs in hypertriglyceridemic rats . In zebrafish, a deficiency of Vit E leads to a depletion of PUFAs , and the amount of Vit E present in tissues is related to the PUFA concentration, especially in the membranes .
en
4. Discussion
biomedical
study
4.507813
[ 0.99951171875, 0.0004131793975830078, 0.0002073049545288086 ]
[ 0.998046875, 0.0004401206970214844, 0.0012178421020507812, 0.0001628398895263672 ]
0.999998
[ "María Elena Soto", "Linaloe Manzano-Pech", "Verónica Guarner-Lans", "Adrían Palacios-Chavarría", "Rafael Ricardo Valdez-Vázquez", "Raúl Martínez-Memije", "Mohammed El-Hafidi", "Félix Leao Rodríguez-Fierros", "Israel Pérez-Torres" ]
https://doi.org/10.3390/cimb46070429
https://creativecommons.org/licenses/by/4.0/
End of preview. Expand in Data Studio

Biomed-Enriched

Biomed-Enriched: A Biomedical Dataset Enriched with LLMs for Pretraining and Extracting Rare and Hidden Content

Dataset Authors

Rian Touchent, Nathan Godey & Eric de la Clergerie
Sorbonne Université, INRIA Paris

Overview

Biomed-Enriched is a PubMed-derived dataset created using a two-stage annotation process. Initially, Llama 3.1 70B Instruct annotated 400K paragraphs for document type, domain, and educational quality. These annotations were then used to fine-tune a smaller model, which propagated the labels across the entire PubMed Central Open Access corpus. This process yielded 2M clinical case paragraphs, with over 450K high-quality paragraphs licensed for commercial use. This dataset provides a large-scale, openly available alternative to private clinical text. In continual pre-training experiments with OLMo2, curated subsets showed targeted improvements: clinical upsampling boosted MMLU ProfMed scores by ~5%, and educational quality filtering improved MedQA and MedMCQA by ~1%. Combining these methods achieved similar performance compared to standard continual-pretraining with just one-third of the training tokens, highlighting the potential for more efficient biomedical pretraining.

The dataset is structured into two primary splits:

  • Commercial
  • Non-Commercial

Dataset Structure

Commercial Split

  • text: Textual content of the paragraphs.
  • path: Precise XML path referencing original paragraph locations.
  • license_url: URL linking to the license.
  • authors: Comprehensive list of authors per paragraph for proper attribution compliance.

Non-Commercial Split

  • path: Precise XML path referencing original paragraph locations.
  • license_url: URL linking to the license.
  • authors: Comprehensive list of authors per paragraph for proper attribution compliance.

Note: The non-commercial split does not contain text data due to licensing restrictions. However, we provide scripts to populate the text field from a local PMC Open Access XML dump. See below for installation and usage instructions.

pip install biomed-enriched

With Python

from biomed_enriched import populate

DATASET_DIR = "/path/to/biomed-enriched"  # input dataset
PMC_XML_ROOT = "/path/to/pmc/non-comm/xml"          # PMC XML dump
OUTPUT_DIR = "/path/to/populated-biomed-enriched"  # drop arg to overwrite in-place

populate(DATASET_DIR, PMC_XML_ROOT, output_path=OUTPUT_DIR, splits="noncommercial", num_proc=1)

The call overwrites the dataset in-place, adding a new text column as the third column (after article_id, path).

With CLI

biomed-enriched \
  --input /path/to/biomed-enriched \
  --xml-root /path/to/pmc/non-comm/xml \
  --num-proc 8

Add --output DIR if you prefer writing to a new directory instead of overwriting.

Annotation Process

The dataset was created using a two-stage annotation framework:

  1. Initial Annotation by Large Language Model:
  • Annotated a subset of paragraphs for the following categories:
  • Document Type: Categorizes the structure and purpose of the content.
    • Clinical Case: Detailed report of symptoms, diagnosis, treatment, and follow-up of individual patients.
    • Study: Research paragraph with methods, results, and discussion of experiments or observations.
    • Review: Summary or synthesis of current knowledge on a specific topic.
    • Other: Content not fitting above categories (editorials, commentaries, policy paragraphs).
  • Domain: Identifies the subject area focus.
    • Clinical: Content relating to patient care, clinical trials, case reports, or practice guidelines.
    • Biomedical: Scientific aspects of medicine and biology.
    • Other: Content mentioning biomedical topics but focusing on administrative, policy, or general communications.
  • Educational Quality: Assesses pedagogical value for college-level biomedical learning on a scale from 1 (minimal value) to 5 (exceptional value) inspired by FineWeb-edu.
    • Score 1: Basic information relevant to biomedical topics, may contain irrelevant content.
    • Score 2: Addresses biomedical education elements but with limitations in coherence or depth.
    • Score 3: Appropriate for college-level curricula, introduces key concepts with reasonable coherence.
    • Score 4: Highly relevant educational content with clear writing style, minimal irrelevant information.
    • Score 5: Outstanding educational value, detailed reasoning with profound insights for college-level learning.
  1. Annotation Scaling via Model Distillation:
  • These annotations were distilled into a XLM-RoBERTa-base model, enabling scalability to the entire PMC dataset.

Annotation Statistics

Here is the distribution of educational scores per domain:

Educational Score Biomedical (n=116 221 134) Clinical (n=2 182 784) Other (n=15 213 051)
1 1.8 % 6.0 % 60.1 %
2 9.4 % 23.4 % 29.4 %
3 10.9 % 26.6 % 8.3 %
4 75.3 % 44.0 % 2.1 %
5 2.6 %

Here is the distribution of educational scores per document type:

Educational Score Study (n=100 387 809) Review (n=6 811 226) Clinical case (n=2 122 403) Other (n=24 295 531)
1 0.7 % 0.3 % 4.0 % 43.4 %
2 7.9 % 1.6 % 14.4 % 30.9 %
3 10.0 % 5.0 % 24.6 % 14.6 %
4 78.7 % 86.9 % 57.0 % 11.1 %
5 2.6 % 6.1 % 0.0 % 0.0 %

Language Distribution

Language Articles Paragraphs Clinical Case Paragraphs % Clinical Cases
en 4,113,275 131,579,445 2,113,185 1.61
es 4,339 181,779 1,235 0.68
zh-cn 3,649 59,719 0 0.00
fr 3,410 173,325 2,586 1.49
de 2,976 248,608 51 0.02
it 2,708 274,819 521 0.19
pt 934 85,242 4,540 5.33
ko 636 25,535 0 0.00
ru 222 10,553 0 0.00
id 189 91,865 15 0.02

Key Applications

  • Improve efficiency in biomedical pretraining by focusing on high-quality, specific content.
  • Create new biomedical subsets tailored to specific research needs based on document type and domain.

Evaluation

Our evaluation focuses on isolating the effects of data curation rather than pursuing state-of-the-art scores on benchmarks. A more powerful foundation model would likely yield higher absolute scores but would obscure the precise impact of our dataset. We therefore selected OLMo2-7B-stage1 as our foundation model, as this intermediate checkpoint provides strong baseline capabilities while allowing for a clear attribution of performance gains to our enrichment strategies. This model has already developed strong language modeling capabilities but precedes the knowledge-intensive tuning of stage 2, providing an ideal balance without the risk of catastrophic forgetting of instruction-following abilities during domain adaptation. Notably, the data mix used in phase 1 includes DCLM, a dataset filtered from web data using a classifier trained on instruction data, which gives OLMo2-7B relatively strong question-answering capabilities even after stage 1.

Each Biomed-Enriched variant was trained for exactly 33.6 billion tokens using identical hyperparameters. We follow the annealing strategy of OLMo2 used in the mid-training phase. By maintaining strict parameter parity across experiments, we created a controlled environment focused solely on measuring the effectiveness of different data curation strategies.

These experiments are designed to illustrate how our granular annotations enable targeted improvements in model capabilities. For instance, by specifically upsampling clinical content (BE-Clinical and BE-ClinicalCase variants), we expect to see a notable increase in performance on the MMLU Professional Medicine benchmark, underscoring the dataset's potential for developing specialized models.

The following variants were created for this evaluation:

  • BE-Base: The complete unmodified PMC Open Access Subset serving as baseline.
  • BE-Educational: Preserves all articles but removes paragraphs with educational quality scores below 3.
  • BE-Clinical: Replicates articles with predominantly clinical domain content 10× in the training mix.
  • BE-ClinicalCase: Replicates articles containing at least one clinical case paragraph 10× to increase exposure to clinical narratives.
  • BE-Prefix: Prefixes each paragraph with its predicted annotations to allow modeling of metadata-content relationships.
  • BE-French: Upsamples articles containing French text 10× to address language imbalance.
  • BE-All: Combines quality filtering (score ≥ 3), upsampling of clinical content, French text, and clinical cases, plus metadata prefixing.

Performance Results

SOTA Models for reference

Model MedQA MedMCQA PubMedQA Anat Clin Bio Med Gen Prof Avg
Llama-3-8B 59.70 57.47 74.80 68.89 74.72 78.47 61.85 83.00 70.22 69.90
Meditron-70B 57.10 46.80 76.60 53.30 66.70 76.30 63.00 69.00 71.60 64.49

Benchmark Results by Dataset Variant (continual pre-training of OLMo2-7B-stage1)

Variant MedQA MedMCQA PubMedQA Anat Clin Bio Med Gen Prof Avg
OLMo2-7B-stage1 45.33 41.14 75.60 54.81 63.40 69.44 53.18 69.00 59.93 59.09
BE-Base 44.85 41.91 76.40 57.04 64.15 70.83 59.54 69.00 59.93 60.41
BE-Clinical 41.95 39.35 76.60 53.33 63.40 65.28 58.38 66.00 63.97 58.70
BE-ClinicalCase 42.11 39.52 76.60 57.04 64.91 66.67 59.54 69.00 62.87 59.81
BE-Prefix 45.72 41.76 77.80 57.04 64.53 68.75 57.23 66.00 61.76 60.07
BE-Educational 45.64 43.08 77.00 57.04 65.28 68.06 56.65 71.00 58.82 60.29
BE-All 47.21 42.79 76.60 60.00 65.66 68.06 58.96 69.00 61.40 61.08

Note: The first three columns represent Medical QA benchmarks. The following six (Anat, Clin, Bio, Med, Gen, Prof) are sub-tasks from MMLU Medical. MMLU abbreviations: Anat=Anatomy, Clin=Clinical Knowledge, Bio=College Biology, Med=College Medicine, Gen=Medical Genetics, Prof=Professional Medicine.

Results Analysis

Overall performance. BE-All achieved the highest average performance across benchmarks at 61.08%, surpassing BE-Base (60.41%) by a small but consistent margin (+0.67 pts, see table above). Its strongest improvements appeared in MedQA (47.21%), MMLU Anatomy (60.00%), and Clinical Knowledge (65.66%), suggesting the effectiveness of combining multiple targeted enrichment strategies.

Clinical enrichment. Clinical enrichment (BE-Clinical) significantly boosted performance on MMLU Professional Medicine benchmark (63.97%, +4.04 pts vs. BE-Base, Figure 2). This improvement was stable from early training, highlighting how clinical narratives enhance the model’s clinical reasoning abilities efficiently.

Educational filtering. Educational filtering (BE-Educational) consistently improved performance on medical question-answering tasks, notably Medical Genetics (71.00%, +2 pts), MedMCQA (43.08%, +1.17 pts), and PubMedQA (77.00%, +0.6 pts). These tasks likely benefit from the knowledge present in educationally high-quality paragraphs (Figure 2).

Metadata prefixing. Metadata prefixing (BE-Prefix) specifically improved performance on PubMedQA (77.80%, +1.4 pts vs. BE-Base). Providing explicit paragraph-level metadata helped primarily with structured document comprehension, but it had limited benefits for other tasks.

General biomedical knowledge trade-off. BE-Base performed better on College Biology (70.83%) than others. Building a biology variant (BE-Bio) could be an interesting future direction, as the current dataset does not specifically target this domain.

Non-English enrichment. BE-French showed clear improvements in French medical QA (FrenchMedMCQA), achieving 40.5% accuracy, significantly surpassing BE-Base and the OLMo2-7B-stage1 baseline (38.32%, Figure 1). These results illustrate effective adaptation to non-English contexts without modifying the underlying model architecture.

Benchmark Results

Data efficiency and training stability. As shown in Figure 2, BE-All reached robust benchmark performance using roughly one-third of the tokens required by BE-Base. Individual enrichments (Educational, Clinical) also displayed early and stable improvements, underscoring potential reductions in training time and computational cost.

Benchmark Results

Licensing

The Biomed-Enriched annotations (document type, domain, educational quality scores, and metadata) are released under the MIT License.

The textual content licensing depends on the individual article licenses from PubMed Central Open Access. Each paragraph includes a license_url field pointing to the specific license. Users must comply with the respective license terms when using the textual data.

How to Cite

Please cite Biomed-Enriched using:

@misc{touchent2025biomedenrichedbiomedicaldatasetenriched,
      title={Biomed-Enriched: A Biomedical Dataset Enriched with LLMs for Pretraining and Extracting Rare and Hidden Content}, 
      author={Rian Touchent and Nathan Godey and Eric de la Clergerie},
      year={2025},
      eprint={2506.20331},
      archivePrefix={arXiv},
      primaryClass={cs.CL},
      url={https://arxiv.org/abs/2506.20331}, 
}
Downloads last month
77

Collection including almanach/Biomed-Enriched